FHIR IG analytics| Package | noma.fhir.mpd |
| Resource Type | CodeSystem |
| Id | ATC_Antineoplastic_immunomodulating_agents.json |
| FHIR Version | R4 |
| Source | https://simplifier.net/resolve?scope=noma.fhir.mpd@2.0.0&canonical=https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480 |
| URL | https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480 |
| Status | active |
| Name | Anatomical Therapeutic Chemical classification system - Human - Antineoplastic and immunomodulating agents Examples |
| Content | complete |
No resources found
No resources found
No narrative content found in resource
FHIR
FHIRsmith{
"resourceType": "CodeSystem",
"id": "849bc27b-a66d-49ad-9389-d8f19d63b480",
"meta": {
"versionId": "1",
"lastUpdated": "2025-08-11T08:51:38.179+00:00"
},
"url": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"identifier": [
{
"system": "http://legemiddelverket.no/fhir/SAFEST/SafestCodeSystemID",
"value": "849bc27b-a66d-49ad-9389-d8f19d63b480"
},
{
"system": "http://legemiddelverket.no/fhir/SAFEST/ListID",
"value": "100000096613"
}
],
"name": "Anatomical Therapeutic Chemical classification system - Human - Antineoplastic and immunomodulating agents Examples",
"status": "active",
"content": "complete",
"property": [
{
"code": "parentATC",
"description": "Parent ATC",
"type": "Coding"
},
{
"code": "fromDate",
"description": "From Date",
"type": "Coding"
},
{
"code": "toDate",
"description": "To Date",
"type": "Coding"
},
{
"code": "previousVersion",
"description": "Previous Version",
"type": "Coding"
},
{
"code": "ATCCode",
"description": "ATC Code",
"type": "Coding"
},
{
"code": "internalCode",
"description": "Internal code",
"type": "Coding"
},
{
"code": "termIdRms",
"description": "RMS ID",
"type": "Coding"
},
{
"code": "internalTermStatus",
"description": "Status (internal)",
"type": "Coding"
},
{
"code": "sourceTermStatus",
"description": "Status (RMS)",
"type": "Coding"
}
],
"concept": [
{
"code": "L04AK",
"display": "Dihydroorotate dehydrogenase (DHODH) inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Dihydroorotate dehydrogenase (DHODH) inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Dihydroorotatdehydrogenase (DHODH) hemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04A",
"display": "Immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AK",
"display": "L04AK"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-10-30T00:00:00Z",
"display": "2023-10-30T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AK"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01CA",
"display": "Vinca alkaloids and analogues",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vinca alkaloids and analogues"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vinkaalkaloider og analoger"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01C",
"display": "Plant alkaloids and other natural products"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CA",
"display": "L01CA"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CA"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX62",
"display": "Ivosidenib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ivosidenib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ivosidenib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX62",
"display": "L01XX62"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-04-11T00:00:00Z",
"display": "2019-04-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2025-01-15T00:00:00Z",
"display": "2025-01-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX62"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XF03",
"display": "Bexarotene",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Bexarotene"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Beksaroten"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XF",
"display": "Retinoids for cancer treatment"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX25",
"display": "Bexarotene"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XF03",
"display": "L01XF03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XF03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AB02",
"display": "Treosulfan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Treosulfan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Treosulfan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AB",
"display": "Alkyl sulfonates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AB02",
"display": "L01AB02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AB02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01CA01",
"display": "Vinblastine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vinblastine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vinblastin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01CA",
"display": "Vinca alkaloids and analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CA01",
"display": "L01CA01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CA01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01CB",
"display": "Podophyllotoxin derivatives",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Podophyllotoxin derivatives"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Podofyllotoksinderivater"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01C",
"display": "Plant alkaloids and other natural products"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CB",
"display": "L01CB"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CB"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XH06",
"display": "Tucidinostat",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tucidinostat"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tucidinostat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XH",
"display": "Histone deacetylase (HDAC) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XH06",
"display": "L01XH06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XH06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE19",
"display": "Ridaforolimus",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ridaforolimus"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ridaforolimus"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE19",
"display": "L01XE19"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2013-01-28T00:00:00Z",
"display": "2013-01-28T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE19"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01AA02",
"display": "Chlorambucil",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Chlorambucil"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Klorambucil"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AA",
"display": "Nitrogen mustard analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AA02",
"display": "L01AA02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AA02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BG",
"display": "Aromatase inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Aromatase inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Aromatasehemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02B",
"display": "Hormone antagonists and related agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BG",
"display": "L02BG"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BG"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AA09",
"display": "Sargramostim",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sargramostim"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sargramostim"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AA",
"display": "Colony stimulating factors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AA09",
"display": "L03AA09"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AA09"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FA",
"display": "CD20 (Clusters of differentitation 20) inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "CD20 (Clusters of differentitation 20) inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "CD20 (Differensieringsantigen 20) hemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01F",
"display": "Monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FA",
"display": "L01FA"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-05-03T00:00:00Z",
"display": "2021-05-03T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FA"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX04",
"display": "Ipilimumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ipilimumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ipilimumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC11",
"display": "Ipilimumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX04",
"display": "L01FX04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA46",
"display": "Itacitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Itacitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Itakitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA46",
"display": "L04AA46"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-11-11T00:00:00Z",
"display": "2020-11-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA46"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01FB",
"display": "CD22 (Clusters of differentitation 22) inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "CD22 (Clusters of differentitation 22) inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "CD22 (Differensieringsantigen 22) hemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01F",
"display": "Monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FB",
"display": "L01FB"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-05-03T00:00:00Z",
"display": "2021-05-03T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FB"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EG04",
"display": "Sirolimus",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sirolimus"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sirolimus"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EG",
"display": "Mammalian target of rapamycin (mTOR) kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EG04",
"display": "L01EG04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EG04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AB60",
"display": "Peginterferon-alfa-2b, combinations",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Peginterferon-alfa-2b, combinations"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Peginterferon alfa-2b, kombinasjoner"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AB",
"display": "Interferons"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AB60",
"display": "L03AB60"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2007-03-04T00:00:00Z",
"display": "2007-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AB60"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA38",
"display": "Ozanimod",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ozanimod"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ozanimod"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA38",
"display": "L04AA38"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2018-07-11T00:00:00Z",
"display": "2018-07-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA38"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EM04",
"display": "Duvelisib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Duvelisib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Duvelisib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EM",
"display": "Phosphatidylinositol-3-kinase (Pi3K) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EM04",
"display": "L01EM04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-11-11T00:00:00Z",
"display": "2020-11-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EM04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XF",
"display": "Retinoids for cancer treatment",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Retinoids for cancer treatment"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Retinoider for kreftbehandling"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01X",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XF",
"display": "L01XF"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-13T00:00:00Z",
"display": "2020-10-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XF"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FG02",
"display": "Ramucirumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ramucirumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ramucirumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FG",
"display": "VEGF/VEGFR (Vascular endothelial growth factor) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC21",
"display": "Ramucirumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FG02",
"display": "L01FG02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FG02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EK03",
"display": "Tivozanib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tivozanib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tivozanib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EK",
"display": "Vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE34",
"display": "Tivozanib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EK03",
"display": "L01EK03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EK03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AX22",
"display": "Leniolisib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Leniolisib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Leniolisib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX22",
"display": "L03AX22"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX22"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE52",
"display": "Quizartinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Quizartinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kizartinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE52",
"display": "L01XE52"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-04-11T00:00:00Z",
"display": "2019-04-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE52"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XH04",
"display": "Belinostat",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Belinostat"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Belinostat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XH",
"display": "Histone deacetylase (HDAC) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX49",
"display": "Belinostat"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XH04",
"display": "L01XH04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XH04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX",
"display": "Other antineoplastic agents",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Other antineoplastic agents"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Andre antineoplastiske midler"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01X",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX",
"display": "L01XX"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX54",
"display": "Niraparib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Niraparib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Niraparib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX54",
"display": "L01XX54"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2017-01-11T00:00:00Z",
"display": "2017-01-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX54"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L02AA04",
"display": "Fosfestrol",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Fosfestrol"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Fosfestrol"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02AA",
"display": "Estrogens"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02AA04",
"display": "L02AA04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02AA04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EN03",
"display": "Infigratinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Infigratinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Infigratinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EN",
"display": "Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EN03",
"display": "L01EN03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-11-08T00:00:00Z",
"display": "2021-11-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EN03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE04",
"display": "Sunitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sunitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sunitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE04",
"display": "L01XE04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2007-01-01T00:00:00Z",
"display": "2007-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XX36",
"display": "Oblimersen",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Oblimersen"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Oblimersen"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX36",
"display": "L01XX36"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX36"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FG",
"display": "VEGF/VEGFR (Vascular endothelial growth factor) inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "VEGF/VEGFR (Vascular endothelial growth factor) inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "VEGF/VEGFR (Vaskulær endotel vekstfaktor) hemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01F",
"display": "Monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FG",
"display": "L01FG"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-05-03T00:00:00Z",
"display": "2021-05-03T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FG"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE38",
"display": "Cobimetinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cobimetinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kobimetinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE38",
"display": "L01XE38"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2016-02-09T00:00:00Z",
"display": "2016-02-09T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE38"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XD",
"display": "Sensitizers used in photodynamic/radiation therapy",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sensitizers used in photodynamic/radiation therapy"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Aktiverende midler til fotodynamisk- og stråleterapi"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01X",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XD",
"display": "L01XD"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2007-03-04T00:00:00Z",
"display": "2007-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XD"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX42",
"display": "Panobinostat",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Panobinostat"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Panobinostat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX42",
"display": "L01XX42"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2012-01-01T00:00:00Z",
"display": "2012-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX42"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AG04",
"display": "Belimumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Belimumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Belimumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AG",
"display": "Monoclonal antibodies"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA26",
"display": "Belimumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AG04",
"display": "L04AG04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AG04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AC14",
"display": "Sarilumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sarilumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sarilumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC14",
"display": "L04AC14"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2016-06-28T00:00:00Z",
"display": "2016-06-28T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC14"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AX14",
"display": "Histamine dihydrochloride",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Histamine dihydrochloride"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Histamindihydroklorid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX14",
"display": "L03AX14"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2006-11-21T00:00:00Z",
"display": "2006-11-21T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX14"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BX01",
"display": "Abarelix",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Abarelix"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Abareliks"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BX",
"display": "Other hormone antagonists and related agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BX01",
"display": "L02BX01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2007-03-04T00:00:00Z",
"display": "2007-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BX01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX14",
"display": "Polatuzumab vedotin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Polatuzumab vedotin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Polatuzumabvedotin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC37",
"display": "Polatuzumab vedotin"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX14",
"display": "L01FX14"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX14"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AE02",
"display": "Ozanimod",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ozanimod"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ozanimod"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AE",
"display": "Sphingosine-1-phosphate (S1P) receptor modulators"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA38",
"display": "Ozanimod"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AE02",
"display": "L04AE02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AE02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AC02",
"display": "Triaziquone",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Triaziquone"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Triazikon"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AC",
"display": "Ethylene imines"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AC02",
"display": "L01AC02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AC02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XL12",
"display": "Obecabtagene autoleucel",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Obecabtagene autoleucel"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Obekabtagenautoleucel"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XL",
"display": "Antineoplastic cell and gene therapy"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XL12",
"display": "L01XL12"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XL12"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AF07",
"display": "Deucravacitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Deucravacitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Deukravacitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AF",
"display": "Janus-associated kinase (JAK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA56",
"display": "Deucravacitinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AF07",
"display": "L04AF07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-04-19T00:00:00Z",
"display": "2023-04-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AF07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EC02",
"display": "Dabrafenib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Dabrafenib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Dabrafenib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EC",
"display": "B-Raf serine-threonine kinase (BRAF) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE23",
"display": "Dabrafenib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EC02",
"display": "L01EC02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EC02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX12",
"display": "Tafasitamab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tafasitamab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tafasitamab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC35",
"display": "Tafasitamab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX12",
"display": "L01FX12"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX12"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01DB11",
"display": "Pixantrone",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pixantrone"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Piksantron"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01DB",
"display": "Anthracyclines and related substances"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01DB11",
"display": "L01DB11"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2010-11-29T00:00:00Z",
"display": "2010-11-29T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01DB11"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AB",
"display": "Alkyl sulfonates",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Alkyl sulfonates"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Alkylsulfonater"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01A",
"display": "Alkylating agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AB",
"display": "L01AB"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AB"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AE03",
"display": "Siponimod",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Siponimod"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Siponimod"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AE",
"display": "Sphingosine-1-phosphate (S1P) receptor modulators"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA42",
"display": "Siponimod"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AE03",
"display": "L04AE03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AE03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX67",
"display": "Tagraxofusp",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tagraxofusp"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tagraksofusp"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX67",
"display": "L01XX67"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-12-16T00:00:00Z",
"display": "2019-12-16T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX67"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AX03",
"display": "Methotrexate",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Methotrexate"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Metotreksat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AX",
"display": "Other immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AX03",
"display": "L04AX03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2004-03-11T00:00:00Z",
"display": "2004-03-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AX03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE13",
"display": "Afatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Afatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Afatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE13",
"display": "L01XE13"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2011-01-01T00:00:00Z",
"display": "2011-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE13"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XC31",
"display": "Avelumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Avelumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Avelumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC31",
"display": "L01XC31"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2017-11-01T00:00:00Z",
"display": "2017-11-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC31"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EM02",
"display": "Copanlisib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Copanlisib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kopanlisib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EM",
"display": "Phosphatidylinositol-3-kinase (Pi3K) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX61",
"display": "Copanlisib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EM02",
"display": "L01EM02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EM02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AA14",
"display": "Lipegfilgrastim",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Lipegfilgrastim"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Lipegfilgrastim"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AA",
"display": "Colony stimulating factors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AA14",
"display": "L03AA14"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2013-01-29T00:00:00Z",
"display": "2013-01-29T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AA14"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AC02",
"display": "Oprelvekin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Oprelvekin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Oprelvekin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AC",
"display": "Interleukins"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AC02",
"display": "L03AC02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AC02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BG02",
"display": "Formestane",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Formestane"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Formestan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BG",
"display": "Aromatase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BG02",
"display": "L02BG02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BG02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC32",
"display": "Atezolizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Atezolizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Atezolizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC32",
"display": "L01XC32"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2017-09-21T00:00:00Z",
"display": "2017-09-21T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC32"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AF08",
"display": "Ritlecitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ritlecitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ritlecitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AF",
"display": "Janus-associated kinase (JAK) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AF08",
"display": "L04AF08"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-08-04T00:00:00Z",
"display": "2023-08-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AF08"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA59",
"display": "Avacopan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Avacopan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Avakopan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA59",
"display": "L04AA59"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA59"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XX64",
"display": "Entinostat",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Entinostat"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Entinostat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX64",
"display": "L01XX64"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-04-11T00:00:00Z",
"display": "2019-04-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX64"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XE21",
"display": "Regorafenib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Regorafenib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Regorafenib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE21",
"display": "L01XE21"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2012-06-06T00:00:00Z",
"display": "2012-06-06T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE21"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XE26",
"display": "Cabozantinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cabozantinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kabozantinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE26",
"display": "L01XE26"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2013-11-15T00:00:00Z",
"display": "2013-11-15T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE26"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XL08",
"display": "Lisocabtagene maraleucel",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Lisocabtagene maraleucel"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Lisokabtagenmaraleucel"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XL",
"display": "Antineoplastic cell and gene therapy"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XL08",
"display": "L01XL08"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XL08"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX",
"display": "Other protein kinase inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Other protein kinase inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Andre proteinkinasehemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01E",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX",
"display": "L01EX"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-13T00:00:00Z",
"display": "2020-10-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AG10",
"display": "Inebilizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Inebilizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Inebilizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AG",
"display": "Monoclonal antibodies"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA47",
"display": "Inebilizumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AG10",
"display": "L04AG10"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AG10"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AB07",
"display": "Opinercept",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Opinercept"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Opinercept"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AB",
"display": "Tumor necrosis factor alpha (TNF-alpha) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AB07",
"display": "L04AB07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-04-11T00:00:00Z",
"display": "2019-04-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AB07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AX03",
"display": "BCG vaccine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "BCG vaccine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "BCG vaksine"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX03",
"display": "L03AX03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EE03",
"display": "Binimetinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Binimetinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Binimetinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EE",
"display": "Mitogen-activated protein kinase (MEK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE41",
"display": "Binimetinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EE03",
"display": "L01EE03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EE03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA13",
"display": "Leflunomide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Leflunomide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Leflunomid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA13",
"display": "L04AA13"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA13"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EM05",
"display": "Parsaclisib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Parsaclisib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Parsaklisib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EM",
"display": "Phosphatidylinositol-3-kinase (Pi3K) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EM05",
"display": "L01EM05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EM05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AX08",
"display": "Darvadstrocel",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Darvadstrocel"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Darvadstrocel"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AX",
"display": "Other immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AX08",
"display": "L04AX08"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-12-16T00:00:00Z",
"display": "2019-12-16T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AX08"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AA",
"display": "Nitrogen mustard analogues",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Nitrogen mustard analogues"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sennepsgassanaloger"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01A",
"display": "Alkylating agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AA",
"display": "L01AA"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AA"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AX05",
"display": "Pirfenidone",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pirfenidone"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pirfenidon"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AX",
"display": "Other immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AX05",
"display": "L04AX05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2011-03-17T00:00:00Z",
"display": "2011-03-17T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AX05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA32",
"display": "Apremilast",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Apremilast"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Apremilast"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA32",
"display": "L04AA32"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2013-12-10T00:00:00Z",
"display": "2013-12-10T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA32"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01BA05",
"display": "Pralatrexate",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pralatrexate"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pralatreksat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BA",
"display": "Folic acid analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BA05",
"display": "L01BA05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2010-01-01T00:00:00Z",
"display": "2010-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BA05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX05",
"display": "Hydroxycarbamide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Hydroxycarbamide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Hydroksykarbamid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX05",
"display": "L01XX05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC38",
"display": "Isatuximab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Isatuximab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Isatuksimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC38",
"display": "L01XC38"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-06-22T00:00:00Z",
"display": "2020-06-22T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC38"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EX11",
"display": "Quizartinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Quizartinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kvizartinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE52",
"display": "Quizartinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX11",
"display": "L01EX11"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX11"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC40",
"display": "Dostarlimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Dostarlimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Dostarlimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC40",
"display": "L01XC40"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-11-11T00:00:00Z",
"display": "2020-11-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC40"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XX10",
"display": "Masoprocol",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Masoprocol"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Masoprokol"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX10",
"display": "L01XX10"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX10"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AX01",
"display": "Azathioprine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Azathioprine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Azatioprin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AX",
"display": "Other immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AX01",
"display": "L04AX01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AX01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XH03",
"display": "Panobinostat",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Panobinostat"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Panobinostat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XH",
"display": "Histone deacetylase (HDAC) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX42",
"display": "Panobinostat"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XH03",
"display": "L01XH03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XH03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EF01",
"display": "Palbociclib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Palbociclib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Palbociklib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EF",
"display": "Cyclin-dependent kinases (CDK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE33",
"display": "Palbociclib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EF01",
"display": "L01EF01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EF01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AB03",
"display": "Interferon gamma",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Interferon gamma"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Interferon gamma"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AB",
"display": "Interferons"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AB03",
"display": "L03AB03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AB03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC12",
"display": "Brentuximab vedotin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Brentuximab vedotin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Brentuksimabvedotin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC12",
"display": "L01XC12"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2011-06-30T00:00:00Z",
"display": "2011-06-30T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC12"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AE01",
"display": "Fingolimod",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Fingolimod"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Fingolimod"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AE",
"display": "Sphingosine-1-phosphate (S1P) receptor modulators"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA27",
"display": "Fingolimod"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AE01",
"display": "L04AE01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AE01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EA03",
"display": "Nilotinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Nilotinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Nilotinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EA",
"display": "BCR-ABL tyrosine kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE08",
"display": "Nilotinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EA03",
"display": "L01EA03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EA03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AG01",
"display": "Etoglucid",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Etoglucid"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Etoglucid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AG",
"display": "Epoxides"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AG01",
"display": "L01AG01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AG01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01DA",
"display": "Actinomycines",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Actinomycines"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Aktinomyciner"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01D",
"display": "Cytotoxic antibiotics and related substances"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01DA",
"display": "L01DA"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01DA"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02A",
"display": "Hormones and related agents",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Hormones and related agents"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Hormoner og beslektede substanser"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02",
"display": "Endocrine therapy"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02A",
"display": "L02A"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02A"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX06",
"display": "Masitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Masitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Masitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE22",
"display": "Masitinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX06",
"display": "L01EX06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AC08",
"display": "Canakinumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Canakinumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kanakinumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC08",
"display": "L04AC08"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2010-01-01T00:00:00Z",
"display": "2010-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC08"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XU",
"display": "Other antineoplastic agents (cont.)",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Other antineoplastic agents (cont.)"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Andre antineoplastiske midler (forts.)"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01X",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XU",
"display": "L01XU"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-12-08T00:00:00Z",
"display": "2024-12-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XU"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FD03",
"display": "Trastuzumab emtansine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Trastuzumab emtansine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Trastuzumabemtansin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FD",
"display": "HER2 (Human epidermal growth factor receptor 2) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC14",
"display": "Trastuzumab emtansine"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FD03",
"display": "L01FD03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FD03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE43",
"display": "Brigatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Brigatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Brigatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE43",
"display": "L01XE43"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2017-01-10T00:00:00Z",
"display": "2017-01-10T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE43"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XX25",
"display": "Bexarotene",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Bexarotene"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Beksaroten"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX25",
"display": "L01XX25"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX25"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XK02",
"display": "Niraparib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Niraparib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Niraparib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XK",
"display": "Poly (ADP-ribose) polymerase (PARP) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX54",
"display": "Niraparib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XK02",
"display": "L01XK02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XK02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AC",
"display": "Ethylene imines",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ethylene imines"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Etyleniminer"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01A",
"display": "Alkylating agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AC",
"display": "L01AC"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AC"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01BC58",
"display": "Decitabine, combinations",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Decitabine, combinations"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Decitabin, kombinasjoner"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BC",
"display": "Pyrimidine analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BC58",
"display": "L01BC58"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-11-22T00:00:00Z",
"display": "2023-11-22T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BC58"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC21",
"display": "Ramucirumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ramucirumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ramucirumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC21",
"display": "L01XC21"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2015-02-17T00:00:00Z",
"display": "2015-02-17T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC21"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EG03",
"display": "Ridaforolimus",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ridaforolimus"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ridaforolimus"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EG",
"display": "Mammalian target of rapamycin (mTOR) kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE19",
"display": "Ridaforolimus"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EG03",
"display": "L01EG03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EG03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX27",
"display": "Arsenic trioxide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Arsenic trioxide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Arsentrioksid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX27",
"display": "L01XX27"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2007-03-04T00:00:00Z",
"display": "2007-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX27"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02AB01",
"display": "Megestrol",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Megestrol"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Megestrol"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02AB",
"display": "Progestogens"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02AB01",
"display": "L02AB01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02AB01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX21",
"display": "Naxitamab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Naxitamab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Naksitamab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX21",
"display": "L01FX21"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX21"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE24",
"display": "Ponatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ponatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ponatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE24",
"display": "L01XE24"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2013-09-02T00:00:00Z",
"display": "2013-09-02T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE24"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XL03",
"display": "Axicabtagene ciloleucel",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Axicabtagene ciloleucel"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Aksikabtagenciloleucel"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XL",
"display": "Antineoplastic cell and gene therapy"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX70",
"display": "Axicabtagene ciloleucel"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XL03",
"display": "L01XL03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-09-09T00:00:00Z",
"display": "2022-09-09T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XL03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01ED02",
"display": "Ceritinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ceritinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ceritinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01ED",
"display": "Anaplastic lymphoma kinase (ALK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE28",
"display": "Ceritinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01ED02",
"display": "L01ED02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01ED02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX66",
"display": "Selinexor",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Selinexor"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Selineksor"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX66",
"display": "L01XX66"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-12-16T00:00:00Z",
"display": "2019-12-16T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX66"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE41",
"display": "Binimetinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Binimetinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Binimetinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE41",
"display": "L01XE41"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2017-01-10T00:00:00Z",
"display": "2017-01-10T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE41"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XK04",
"display": "Talazoparib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Talazoparib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Talazoparib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XK",
"display": "Poly (ADP-ribose) polymerase (PARP) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX60",
"display": "Talazoparib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XK04",
"display": "L01XK04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XK04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX26",
"display": "Mirvetuximab soravtansine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Mirvetuximab soravtansine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Mirvetuksimabsoravtansin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX26",
"display": "L01FX26"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-11-15T00:00:00Z",
"display": "2023-11-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX26"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XY03",
"display": "Nivolumab and relatlimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Nivolumab and relatlimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Nivolumab og relatlimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XY",
"display": "Combinations of antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XY03",
"display": "L01XY03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-09T00:00:00Z",
"display": "2021-12-09T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XY03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XX85",
"display": "Idroxioleic acid",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Idroxioleic acid"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Idroksioleinsyre"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX85",
"display": "L01XX85"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX85"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FY",
"display": "Combinations of monoclonal antibodies and antibody drug conjugates",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Combinations of monoclonal antibodies and antibody drug conjugates"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kombinasjoner av monoklonale antistoffer og antistoff-legemiddelkonjugater"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01F",
"display": "Monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FY",
"display": "L01FY"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-11-14T00:00:00Z",
"display": "2023-11-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FY"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01CD02",
"display": "Docetaxel",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Docetaxel"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Docetaksel"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01CD",
"display": "Taxanes"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CD02",
"display": "L01CD02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CD02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BA02",
"display": "Toremifene",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Toremifene"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Toremifen"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BA",
"display": "Anti-estrogens"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BA02",
"display": "L02BA02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BA02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AJ01",
"display": "Eculizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Eculizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ekulizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AJ",
"display": "Complement inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA25",
"display": "Eculizumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AJ01",
"display": "L04AJ01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AJ01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC14",
"display": "Trastuzumab emtansine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Trastuzumab emtansine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Trastuzumabemtansin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC14",
"display": "L01XC14"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2013-12-10T00:00:00Z",
"display": "2013-12-10T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC14"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01FF02",
"display": "Pembrolizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pembrolizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pembrolizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FF",
"display": "PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) hemmere"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC18",
"display": "Pembrolizumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FF02",
"display": "L01FF02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FF02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX10",
"display": "Olaratumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Olaratumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Olaratumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC27",
"display": "Olaratumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX10",
"display": "L01FX10"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX10"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BX03",
"display": "Abiraterone",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Abiraterone"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Abirateron"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BX",
"display": "Other hormone antagonists and related agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BX03",
"display": "L02BX03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2011-11-02T00:00:00Z",
"display": "2011-11-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BX03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FY02",
"display": "Nivolumab and relatlimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Nivolumab and relatlimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Nivolumab og relatlimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FY",
"display": "Combinations of monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XY03",
"display": "Nivolumab and relatlimab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FY02",
"display": "L01FY02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FY02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XM01",
"display": "Enasidenib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Enasidenib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Enasidenib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XM",
"display": "Isocitrate dehydrogenase (IDH) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX59",
"display": "Enasidenib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XM01",
"display": "L01XM01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-12-08T00:00:00Z",
"display": "2024-12-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XM01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AC18",
"display": "Risankizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Risankizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Risankizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC18",
"display": "L04AC18"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-03-18T00:00:00Z",
"display": "2019-03-18T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC18"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EB04",
"display": "Osimertinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Osimertinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Osimertinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EB",
"display": "Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE35",
"display": "Osimertinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EB04",
"display": "L01EB04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EB04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC22",
"display": "Necitumumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Necitumumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Necitumumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC22",
"display": "L01XC22"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2015-07-06T00:00:00Z",
"display": "2015-07-06T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC22"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XE45",
"display": "Neratinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Neratinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Neratinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE45",
"display": "L01XE45"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2018-07-03T00:00:00Z",
"display": "2018-07-03T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE45"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XC09",
"display": "Catumaxomab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Catumaxomab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Catumaksomab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC09",
"display": "L01XC09"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2009-03-20T00:00:00Z",
"display": "2009-03-20T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC09"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01AA05",
"display": "Chlormethine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Chlormethine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Klormetin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AA",
"display": "Nitrogen mustard analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AA05",
"display": "L01AA05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AA05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX16",
"display": "Oportuzumab monatox",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Oportuzumab monatox"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Oportuzumab monatoks"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX16",
"display": "L01FX16"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-11-08T00:00:00Z",
"display": "2021-11-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX16"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XH05",
"display": "Entinostat",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Entinostat"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Entinostat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XH",
"display": "Histone deacetylase (HDAC) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX64",
"display": "Entinostat"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XH05",
"display": "L01XH05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XH05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AX",
"display": "Other immunosuppressants",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Other immunosuppressants"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Andre immunsuppressive midler"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04A",
"display": "Immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AX",
"display": "L04AX"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AX"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AG05",
"display": "Vedolizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vedolizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vedolizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AG",
"display": "Monoclonal antibodies"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA33",
"display": "Vedolizumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AG05",
"display": "L04AG05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AG05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02AX",
"display": "Other hormones",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Other hormones"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Andre hormoner"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02A",
"display": "Hormones and related agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02AX",
"display": "L02AX"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02AX"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FC01",
"display": "Daratumumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Daratumumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Daratumumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FC",
"display": "CD38 (Clusters of differentitation 38) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC24",
"display": "Daratumumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FC01",
"display": "L01FC01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FC01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FF04",
"display": "Avelumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Avelumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Avelumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FF",
"display": "PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) hemmere"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC31",
"display": "Avelumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FF04",
"display": "L01FF04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FF04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AX19",
"display": "Dasiprotimut-T",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Dasiprotimut-T"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Dasiprotimut-T"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX19",
"display": "L03AX19"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2014-07-15T00:00:00Z",
"display": "2014-07-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX19"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AD",
"display": "Nitrosoureas",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Nitrosoureas"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Nitrosoureaforbindelser"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01A",
"display": "Alkylating agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AD",
"display": "L01AD"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AD"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX25",
"display": "Mosunetuzumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Mosunetuzumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Mosunetuzumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX25",
"display": "L01FX25"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-11-21T00:00:00Z",
"display": "2022-11-21T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX25"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA17",
"display": "Adalimumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Adalimumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Adalimumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA17",
"display": "L04AA17"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-01-01T00:00:00Z",
"display": "2002-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA17"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01BB02",
"display": "Mercaptopurine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Mercaptopurine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Merkaptopurin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BB",
"display": "Purine analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BB02",
"display": "L01BB02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BB02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BX02",
"display": "Degarelix",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Degarelix"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Degareliks"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BX",
"display": "Other hormone antagonists and related agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BX02",
"display": "L02BX02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2009-03-20T00:00:00Z",
"display": "2009-03-20T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BX02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AD02",
"display": "Lomustine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Lomustine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Lomustin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AD",
"display": "Nitrosoureas"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AD02",
"display": "L01AD02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AD02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX72",
"display": "Tazemetostat",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tazemetostat"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tazemetostat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX72",
"display": "L01XX72"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-03-04T00:00:00Z",
"display": "2021-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX72"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AD02",
"display": "Tacrolimus",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tacrolimus"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Takrolimus"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AD",
"display": "Calcineurin inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA05",
"display": "Tacrolimus"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AD02",
"display": "L04AD02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AD02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AB04",
"display": "Interferon alfa-2a",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Interferon alfa-2a"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Interferon alfa-2a"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AB",
"display": "Interferons"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AB04",
"display": "L03AB04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AB04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA36",
"display": "Ocrelizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ocrelizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Okrelizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA36",
"display": "L04AA36"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2016-12-21T00:00:00Z",
"display": "2016-12-21T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA36"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AA53",
"display": "Teprotumumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Teprotumumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Teprotumumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA53",
"display": "L04AA53"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-03-04T00:00:00Z",
"display": "2021-03-04T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA53"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EC01",
"display": "Vemurafenib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vemurafenib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vemurafenib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EC",
"display": "B-Raf serine-threonine kinase (BRAF) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE15",
"display": "Vemurafenib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EC01",
"display": "L01EC01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EC01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA21",
"display": "Efalizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Efalizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Efalizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA21",
"display": "L04AA21"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2004-11-02T00:00:00Z",
"display": "2004-11-02T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA21"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L03AX16",
"display": "Plerixafor",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Plerixafor"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pleriksafor"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX16",
"display": "L03AX16"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2009-03-23T00:00:00Z",
"display": "2009-03-23T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX16"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE25",
"display": "Trametinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Trametinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Trametinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE25",
"display": "L01XE25"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2013-03-06T00:00:00Z",
"display": "2013-03-06T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE25"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XX46",
"display": "Olaparib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Olaparib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Olaparib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX46",
"display": "L01XX46"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2014-02-20T00:00:00Z",
"display": "2014-02-20T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX46"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01BC01",
"display": "Cytarabine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cytarabine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Cytarabin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BC",
"display": "Pyrimidine analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BC01",
"display": "L01BC01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BC01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BX04",
"display": "Relugolix",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Relugolix"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Relugoliks"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BX",
"display": "Other hormone antagonists and related agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BX04",
"display": "L02BX04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-01-07T00:00:00Z",
"display": "2022-01-07T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BX04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE34",
"display": "Tivozanib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tivozanib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tivozanib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE34",
"display": "L01XE34"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2015-07-06T00:00:00Z",
"display": "2015-07-06T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE34"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XE42",
"display": "Ribociclib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ribociclib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ribosiklib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE42",
"display": "L01XE42"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2016-09-06T00:00:00Z",
"display": "2016-09-06T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE42"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L02AA",
"display": "Estrogens",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Estrogens"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Østrogener"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02A",
"display": "Hormones and related agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02AA",
"display": "L02AA"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02AA"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA27",
"display": "Fingolimod",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Fingolimod"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Fingolimod"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA27",
"display": "L04AA27"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2011-01-01T00:00:00Z",
"display": "2011-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA27"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AC01",
"display": "Daclizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Daclizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Daklizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA08",
"display": "Daclizumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC01",
"display": "L04AC01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX70",
"display": "Axicabtagene ciloleucel",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Axicabtagene ciloleucel"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Aksikabtagenciloleucel"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX70",
"display": "L01XX70"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-11-11T00:00:00Z",
"display": "2020-11-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2023-01-13T00:00:00Z",
"display": "2023-01-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX70"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AC26",
"display": "Goflikicept",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Goflikicept"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Goflikicept"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC26",
"display": "L04AC26"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC26"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX28",
"display": "Glofitamab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Glofitamab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Glofitamab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX28",
"display": "L01FX28"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-05-10T00:00:00Z",
"display": "2023-05-10T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX28"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BX53",
"display": "Abiraterone and corticosteroids",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Abiraterone and corticosteroids"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Abirateron og kortikosteroider"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BX",
"display": "Other hormone antagonists and related agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BX53",
"display": "L02BX53"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BX53"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XM02",
"display": "Ivosidenib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ivosidenib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ivosidenib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XM",
"display": "Isocitrate dehydrogenase (IDH) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX62",
"display": "Ivosidenib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XM02",
"display": "L01XM02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-12-08T00:00:00Z",
"display": "2024-12-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XM02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AC20",
"display": "Netakimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Netakimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Netakimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC20",
"display": "L04AC20"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-03-04T00:00:00Z",
"display": "2021-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC20"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XG02",
"display": "Carfilzomib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Carfilzomib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Karfilzomib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XG",
"display": "Proteasome inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX45",
"display": "Carfilzomib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XG02",
"display": "L01XG02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XG02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX10",
"display": "Midostaurin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Midostaurin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Midostaurin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE39",
"display": "Midostaurin"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX10",
"display": "L01EX10"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX10"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AG",
"display": "Monoclonal antibodies",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Monoclonal antibodies"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Monoklonale antistoffer"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04A",
"display": "Immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AG",
"display": "L04AG"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-10-30T00:00:00Z",
"display": "2023-10-30T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AG"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EB01",
"display": "Gefitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Gefitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Gefitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EB",
"display": "Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE02",
"display": "Gefitinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EB01",
"display": "L01EB01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EB01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA33",
"display": "Vedolizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vedolizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vedolizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA33",
"display": "L04AA33"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2014-02-20T00:00:00Z",
"display": "2014-02-20T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA33"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EA02",
"display": "Dasatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Dasatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Dasatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EA",
"display": "BCR-ABL tyrosine kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE06",
"display": "Dasatinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EA02",
"display": "L01EA02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EA02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX02",
"display": "Gemtuzumab ozogamicin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Gemtuzumab ozogamicin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Gemtuzumabozogamicin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC05",
"display": "Gemtuzumab ozogamicin"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX02",
"display": "L01FX02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC37",
"display": "Polatuzumab vedotin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Polatuzumab vedotin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Polatuzumabvedotin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC37",
"display": "L01XC37"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-03-02T00:00:00Z",
"display": "2020-03-02T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC37"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01DC04",
"display": "Ixabepilone",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ixabepilone"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Iksabepilon"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01DC",
"display": "Other cytotoxic antibiotics"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01DC04",
"display": "L01DC04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01DC04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX35",
"display": "Datopotamab deruxtecan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Datopotamab deruxtecan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Datopotamabderukstekan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX35",
"display": "L01FX35"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX35"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX77",
"display": "Adagrasib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Adagrasib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Adagrasib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX77",
"display": "L01XX77"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX77"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX75",
"display": "Tebentafusp",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tebentafusp"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tebentafusp"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX75",
"display": "L01XX75"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-04-25T00:00:00Z",
"display": "2022-04-25T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX75"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01DC02",
"display": "Plicamycin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Plicamycin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Plikamycin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01DC",
"display": "Other cytotoxic antibiotics"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01DC02",
"display": "L01DC02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01DC02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XD01",
"display": "Porfimer sodium",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Porfimer sodium"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Porfimernatrium"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XD",
"display": "Sensitizers used in photodynamic/radiation therapy"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XD01",
"display": "L01XD01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2004-06-09T00:00:00Z",
"display": "2004-06-09T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XD01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FD07",
"display": "Zanidatamab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Zanidatamab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Zanidatamab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FD",
"display": "HER2 (Human epidermal growth factor receptor 2) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FD07",
"display": "L01FD07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FD07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE36",
"display": "Alectinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Alectinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Alektinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE36",
"display": "L01XE36"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2016-02-09T00:00:00Z",
"display": "2016-02-09T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE36"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XE35",
"display": "Osimertinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Osimertinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Osimertinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE35",
"display": "L01XE35"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2016-01-07T00:00:00Z",
"display": "2016-01-07T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE35"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AA01",
"display": "Ciclosporin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ciclosporin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ciklosporin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA01",
"display": "L04AA01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01A",
"display": "Alkylating agents",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Alkylating agents"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Alkyleringsmidler"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01",
"display": "Antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01A",
"display": "L01A"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01A"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01BC08",
"display": "Decitabine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Decitabine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Decitabin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BC",
"display": "Pyrimidine analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BC08",
"display": "L01BC08"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2009-03-20T00:00:00Z",
"display": "2009-03-20T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BC08"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04",
"display": "Immunosuppressants",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Immunosuppressants"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Immunsuppressive midler"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L",
"display": "Antineoplastic and immunomodulating agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04",
"display": "L04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX56",
"display": "Etirinotecan pegol",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Etirinotecan pegol"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Etirinotekan pegol"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX56",
"display": "L01XX56"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2017-01-11T00:00:00Z",
"display": "2017-01-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX56"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L03AB01",
"display": "Interferon alfa natural",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Interferon alfa natural"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Naturlig interferon alfa"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AB",
"display": "Interferons"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AB01",
"display": "L03AB01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AB01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE27",
"display": "Ibrutinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ibrutinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ibrutinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE27",
"display": "L01XE27"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2014-02-20T00:00:00Z",
"display": "2014-02-20T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE27"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01BC07",
"display": "Azacitidine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Azacitidine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Azacitidin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BC",
"display": "Pyrimidine analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BC07",
"display": "L01BC07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2009-02-23T00:00:00Z",
"display": "2009-02-23T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BC07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02AB03",
"display": "Gestonorone",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Gestonorone"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Gestonoron"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02AB",
"display": "Progestogens"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02AB03",
"display": "L02AB03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02AB03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01",
"display": "Antineoplastic agents",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Antineoplastic agents"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Antineoplastiske midler"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L",
"display": "Antineoplastic and immunomodulating agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01",
"display": "L01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AJ08",
"display": "Iptacopan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Iptacopan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Iptakopan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AJ",
"display": "Complement inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AJ08",
"display": "L04AJ08"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-11-15T00:00:00Z",
"display": "2023-11-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AJ08"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AB03",
"display": "Afelimomab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Afelimomab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Afelimomab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AB",
"display": "Tumor necrosis factor alpha (TNF-alpha) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA16",
"display": "Afelimomab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AB03",
"display": "L04AB03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AB03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AB14",
"display": "Cepeginterferon alfa-2b",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cepeginterferon alfa-2b"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Cepeginterferon alfa-2b"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AB",
"display": "Interferons"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AB14",
"display": "L03AB14"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2014-02-20T00:00:00Z",
"display": "2014-02-20T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AB14"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BB03",
"display": "Bicalutamide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Bicalutamide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Bikalutamid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BB",
"display": "Anti-androgens"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BB03",
"display": "L02BB03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BB03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AC01",
"display": "Aldesleukin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Aldesleukin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Aldesleukin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AC",
"display": "Interleukins"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AC01",
"display": "L03AC01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AC01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AJ11",
"display": "Pozelimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pozelimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pozelimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AJ",
"display": "Complement inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AJ11",
"display": "L04AJ11"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AJ11"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XL10",
"display": "Nadofaragene firadenovec",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Nadofaragene firadenovec"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Nadofaragenfiradenovek"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XL",
"display": "Antineoplastic cell and gene therapy"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XL10",
"display": "L01XL10"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-11-15T00:00:00Z",
"display": "2023-11-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XL10"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01CD04",
"display": "Cabazitaxel",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cabazitaxel"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kabazitaksel"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01CD",
"display": "Taxanes"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CD04",
"display": "L01CD04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2011-04-15T00:00:00Z",
"display": "2011-04-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CD04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03A",
"display": "Immunostimulants",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Immunostimulants"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Immunstimulerende midler"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03",
"display": "Immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03A",
"display": "L03A"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03A"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE29",
"display": "Lenvatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Lenvatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Lenvatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE29",
"display": "L01XE29"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2015-01-22T00:00:00Z",
"display": "2015-01-22T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE29"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AE04",
"display": "Ponesimod",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ponesimod"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ponesimod"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AE",
"display": "Sphingosine-1-phosphate (S1P) receptor modulators"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA50",
"display": "Ponesimod"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AE04",
"display": "L04AE04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AE04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BG04",
"display": "Letrozole",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Letrozole"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Letrozol"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BG",
"display": "Aromatase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BG04",
"display": "L02BG04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BG04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC42",
"display": "Prolgolimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Prolgolimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Prolgolimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC42",
"display": "L01XC42"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-03-04T00:00:00Z",
"display": "2021-03-04T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-01T00:00:00Z",
"display": "2022-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC42"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EX15",
"display": "Pexidartinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pexidartinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Peksidartinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX15",
"display": "L01EX15"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-11-11T00:00:00Z",
"display": "2020-11-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX15"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX03",
"display": "Catumaxomab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Catumaxomab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Katumaksomab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC09",
"display": "Catumaxomab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX03",
"display": "L01FX03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EB",
"display": "Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Epidermal vekstfaktorreseptor (EGFR) tyrosinkinasehemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01E",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EB",
"display": "L01EB"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-13T00:00:00Z",
"display": "2020-10-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EB"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AB11",
"display": "Peginterferon alfa-2a",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Peginterferon alfa-2a"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Peginterferon alfa-2a"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AB",
"display": "Interferons"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AB11",
"display": "L03AB11"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-07-25T00:00:00Z",
"display": "2002-07-25T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AB11"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BA01",
"display": "Tamoxifen",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tamoxifen"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tamoksifen"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BA",
"display": "Anti-estrogens"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BA01",
"display": "L02BA01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BA01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA11",
"display": "Etanercept",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Etanercept"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Etanercept"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA11",
"display": "L04AA11"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA11"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EB06",
"display": "Olmutinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Olmutinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Olmutinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EB",
"display": "Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE40",
"display": "Olmutinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EB06",
"display": "L01EB06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EB06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX86",
"display": "Calaspargase pegol",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Calaspargase pegol"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kalaspargasepegol"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX86",
"display": "L01XX86"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX86"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA44",
"display": "Upadacitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Upadacitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Upadacitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA44",
"display": "L04AA44"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-12-16T00:00:00Z",
"display": "2019-12-16T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA44"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01DC01",
"display": "Bleomycin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Bleomycin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Bleomycin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01DC",
"display": "Other cytotoxic antibiotics"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01DC01",
"display": "L01DC01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01DC01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AX15",
"display": "Mifamurtide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Mifamurtide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Mifamurtid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX15",
"display": "L03AX15"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX15"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L",
"display": "Antineoplastic and immunomodulating agents",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Antineoplastic and immunomodulating agents"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Antineoplastiske og immunmodulerende midler"
}
],
"property": [
{
"code": "ATCCode",
"valueCoding": {
"code": "L",
"display": "L"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA40",
"display": "Cladribine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cladribine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kladribin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA40",
"display": "L04AA40"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2018-07-11T00:00:00Z",
"display": "2018-07-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA40"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XK",
"display": "Poly (ADP-ribose) polymerase (PARP) inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Poly (ADP-ribose) polymerase (PARP) inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Poly (ADP-ribose) polymerasehemmere (PARP)"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01X",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XK",
"display": "L01XK"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-13T00:00:00Z",
"display": "2020-10-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XK"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AX04",
"display": "Dacarbazine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Dacarbazine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Dakarbazin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AX",
"display": "Other alkylating agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AX04",
"display": "L01AX04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AX04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AB17",
"display": "Sampeginterferon beta-1A",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sampeginterferon beta-1A"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sampeginterferon beta-1A"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AB",
"display": "Interferons"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AB17",
"display": "L03AB17"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AB17"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE08",
"display": "Nilotinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Nilotinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Nilotinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE08",
"display": "L01XE08"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE08"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EN",
"display": "Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Fibroblast vekstfaktorreseptor (FGFR) tyrosinkinasehemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01E",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EN",
"display": "L01EN"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-11-08T00:00:00Z",
"display": "2021-11-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EN"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX18",
"display": "Tiazofurine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tiazofurine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tiazofurin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX18",
"display": "L01XX18"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX18"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE39",
"display": "Midostaurin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Midostaurin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Midostaurin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE39",
"display": "L01XE39"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2016-12-20T00:00:00Z",
"display": "2016-12-20T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE39"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01AD08",
"display": "Uramustine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Uramustine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Uramustin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AD",
"display": "Nitrosoureas"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AD08",
"display": "L01AD08"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2018-07-11T00:00:00Z",
"display": "2018-07-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AD08"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AB61",
"display": "Peginterferon alfa-2a, combinations",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Peginterferon alfa-2a, combinations"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Peginterferon alfa-2a, kombinasjoner"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AB",
"display": "Interferons"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AB61",
"display": "L03AB61"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2009-03-23T00:00:00Z",
"display": "2009-03-23T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AB61"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX22",
"display": "Selpercatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Selpercatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Selperkatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX22",
"display": "L01EX22"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-03-04T00:00:00Z",
"display": "2021-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX22"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE06",
"display": "Dasatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Dasatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Dasatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE06",
"display": "L01XE06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2007-01-01T00:00:00Z",
"display": "2007-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XC06",
"display": "Cetuximab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cetuximab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Cetuksimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC06",
"display": "L01XC06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2005-08-02T00:00:00Z",
"display": "2005-08-02T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01BB06",
"display": "Clofarabine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Clofarabine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Klofarabin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BB",
"display": "Purine analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BB06",
"display": "L01BB06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2006-06-27T00:00:00Z",
"display": "2006-06-27T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BB06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX29",
"display": "Denileukin diftitox",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Denileukin diftitox"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Denileukin diftitoks"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX29",
"display": "L01XX29"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-13T00:00:00Z",
"display": "2002-02-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX29"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XF01",
"display": "Tretinoin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tretinoin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tretinoin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XF",
"display": "Retinoids for cancer treatment"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX14",
"display": "Tretinoin"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XF01",
"display": "L01XF01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XF01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE54",
"display": "Gilteritinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Gilteritinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Gilteritinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE54",
"display": "L01XE54"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-04-11T00:00:00Z",
"display": "2019-04-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE54"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XE15",
"display": "Vemurafenib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vemurafenib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vemurafenib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE15",
"display": "L01XE15"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2012-01-01T00:00:00Z",
"display": "2012-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE15"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XC04",
"display": "Alemtuzumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Alemtuzumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Alemtuzumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC04",
"display": "L01XC04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2005-09-15T00:00:00Z",
"display": "2005-09-15T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2015-01-01T00:00:00Z",
"display": "2015-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01BC03",
"display": "Tegafur",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tegafur"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tegafur"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BC",
"display": "Pyrimidine analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BC03",
"display": "L01BC03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BC03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX27",
"display": "Epcoritamab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Epcoritamab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Epkoritamab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX27",
"display": "L01FX27"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-11-15T00:00:00Z",
"display": "2023-11-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX27"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AB",
"display": "Interferons",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Interferons"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Interferoner"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03A",
"display": "Immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AB",
"display": "L03AB"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AB"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EE01",
"display": "Trametinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Trametinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Trametinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EE",
"display": "Mitogen-activated protein kinase (MEK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE25",
"display": "Trametinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EE01",
"display": "L01EE01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EE01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01CE02",
"display": "Irinotecan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Irinotecan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Irinotekan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01CE",
"display": "Topoisomerase 1 inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX19",
"display": "Irinotecan"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CE02",
"display": "L01CE02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CE02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XK06",
"display": "Pamiparib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pamiparib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pamiparib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XK",
"display": "Poly (ADP-ribose) polymerase (PARP) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XK06",
"display": "L01XK06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-03-04T00:00:00Z",
"display": "2021-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XK06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XY04",
"display": "Bifikafusp alfa and onfekafusp alfa",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Bifikafusp alfa and onfekafusp alfa"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Bifikafusp alfa og onfekafusp alfa"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XY",
"display": "Combinations of antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XY04",
"display": "L01XY04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XY04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AA19",
"display": "Eflapegrastim",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Eflapegrastim"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Eflapegrastim"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AA",
"display": "Colony stimulating factors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AA19",
"display": "L03AA19"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-11-15T00:00:00Z",
"display": "2023-11-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AA19"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC35",
"display": "Tafasitamab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tafasitamab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tafasitamab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC35",
"display": "L01XC35"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-12T00:00:00Z",
"display": "2020-10-12T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC35"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XD04",
"display": "Aminolevulinic acid",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Aminolevulinic acid"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Aminolevulinsyre"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XD",
"display": "Sensitizers used in photodynamic/radiation therapy"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XD04",
"display": "L01XD04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2006-06-21T00:00:00Z",
"display": "2006-06-21T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XD04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA23",
"display": "Natalizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Natalizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Natalizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA23",
"display": "L04AA23"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2006-08-11T00:00:00Z",
"display": "2006-08-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA23"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XE32",
"display": "Cediranib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cediranib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Cediranib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE32",
"display": "L01XE32"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2015-07-06T00:00:00Z",
"display": "2015-07-06T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE32"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EH01",
"display": "Lapatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Lapatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Lapatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EH",
"display": "Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE07",
"display": "Lapatinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EH01",
"display": "L01EH01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EH01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC25",
"display": "Mogamulizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Mogamulizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Mogamulizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC25",
"display": "L01XC25"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2016-02-09T00:00:00Z",
"display": "2016-02-09T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC25"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EX13",
"display": "Gilteritinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Gilteritinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Gilteritinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE54",
"display": "Gilteritinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX13",
"display": "L01EX13"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX13"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC01",
"display": "Edrecolomab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Edrecolomab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Edrekolomab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC01",
"display": "L01XC01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01FD01",
"display": "Trastuzumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Trastuzumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Trastuzumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FD",
"display": "HER2 (Human epidermal growth factor receptor 2) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC03",
"display": "Trastuzumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FD01",
"display": "L01FD01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FD01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AJ09",
"display": "Danicopan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Danicopan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Danikopan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AJ",
"display": "Complement inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AJ09",
"display": "L04AJ09"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-11-15T00:00:00Z",
"display": "2023-11-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AJ09"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AA08",
"display": "Prednimustine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Prednimustine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Prednimustin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AA",
"display": "Nitrogen mustard analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AA08",
"display": "L01AA08"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AA08"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC28",
"display": "Durvalumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Durvalumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Durvalumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC28",
"display": "L01XC28"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2017-12-01T00:00:00Z",
"display": "2017-12-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC28"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AF02",
"display": "Baricitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Baricitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Baricitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AF",
"display": "Janus-associated kinase (JAK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA37",
"display": "Baricitinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AF02",
"display": "L04AF02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AF02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX19",
"display": "Sabatolimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sabatolimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sabatolimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX19",
"display": "L01FX19"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX19"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX22",
"display": "Alitretinoin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Alitretinoin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Alitretinoin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX22",
"display": "L01XX22"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX22"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01CB02",
"display": "Teniposide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Teniposide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Teniposid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01CB",
"display": "Podophyllotoxin derivatives"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CB02",
"display": "L01CB02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CB02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02AB",
"display": "Progestogens",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Progestogens"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Progestogener"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02A",
"display": "Hormones and related agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02AB",
"display": "L02AB"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02AB"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AX10",
"display": "Tegomil fumarate",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tegomil fumarate"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tegomilfumarat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AX",
"display": "Other immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AX10",
"display": "L04AX10"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AX10"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AA02",
"display": "Filgrastim",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Filgrastim"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Filgrastim"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AA",
"display": "Colony stimulating factors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AA02",
"display": "L03AA02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AA02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA37",
"display": "Baricitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Baricitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Baricitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA37",
"display": "L04AA37"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2016-12-21T00:00:00Z",
"display": "2016-12-21T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA37"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L03AA13",
"display": "Pegfilgrastim",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pegfilgrastim"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pegfilgrastim"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AA",
"display": "Colony stimulating factors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AA13",
"display": "L03AA13"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2004-03-04T00:00:00Z",
"display": "2004-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AA13"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AD01",
"display": "Carmustine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Carmustine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Karmustin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AD",
"display": "Nitrosoureas"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AD01",
"display": "L01AD01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AD01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01BC02",
"display": "Fluorouracil",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Fluorouracil"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Fluorouracil"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BC",
"display": "Pyrimidine analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BC02",
"display": "L01BC02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BC02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XD07",
"display": "Padeliporfin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Padeliporfin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Padeliporfin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XD",
"display": "Sensitizers used in photodynamic/radiation therapy"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XD07",
"display": "L01XD07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2017-01-10T00:00:00Z",
"display": "2017-01-10T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XD07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC07",
"display": "Bevacizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Bevacizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Bevacizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC07",
"display": "L01XC07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2005-02-24T00:00:00Z",
"display": "2005-02-24T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L03AX10",
"display": "Immunocyanin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Immunocyanin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Immunocyanin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX10",
"display": "L03AX10"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX10"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AA15",
"display": "Balugrastim",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Balugrastim"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Balugrastim"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AA",
"display": "Colony stimulating factors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AA15",
"display": "L03AA15"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2014-02-20T00:00:00Z",
"display": "2014-02-20T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AA15"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AB01",
"display": "Etanercept",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Etanercept"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Etanercept"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AB",
"display": "Tumor necrosis factor alpha (TNF-alpha) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA11",
"display": "Etanercept"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AB01",
"display": "L04AB01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AB01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AJ",
"display": "Complement inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Complement inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Komplementhemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04A",
"display": "Immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AJ",
"display": "L04AJ"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-10-30T00:00:00Z",
"display": "2023-10-30T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AJ"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX20",
"display": "Tremelimumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tremelimumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tremelimumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX20",
"display": "L01FX20"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-08T00:00:00Z",
"display": "2021-12-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX20"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE23",
"display": "Dabrafenib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Dabrafenib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Dabrafenib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE23",
"display": "L01XE23"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2013-10-01T00:00:00Z",
"display": "2013-10-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE23"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AA26",
"display": "Belimumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Belimumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Belimumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA26",
"display": "L04AA26"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2011-01-01T00:00:00Z",
"display": "2011-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA26"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AA04",
"display": "Antithymocyte immunoglobulin (rabbit)",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Antithymocyte immunoglobulin (rabbit)"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Antitymocyttimmunglobulin (kanin)"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA04",
"display": "L04AA04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FD02",
"display": "Pertuzumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pertuzumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pertuzumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FD",
"display": "HER2 (Human epidermal growth factor receptor 2) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC13",
"display": "Pertuzumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FD02",
"display": "L01FD02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FD02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA49",
"display": "Peficitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Peficitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Peficitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA49",
"display": "L04AA49"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-03-04T00:00:00Z",
"display": "2021-03-04T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA49"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XL06",
"display": "Brexucabtagene autoleucel",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Brexucabtagene autoleucel"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Breksukabtagenautoleucel"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XL",
"display": "Antineoplastic cell and gene therapy"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XL06",
"display": "L01XL06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XL06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01ED",
"display": "Anaplastic lymphoma kinase (ALK) inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Anaplastic lymphoma kinase (ALK) inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Anaplastisk lymfomkinasehemmere (ALK)"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01E",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01ED",
"display": "L01ED"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-13T00:00:00Z",
"display": "2020-10-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01ED"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AA10",
"display": "Melphalan flufenamide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Melphalan flufenamide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Melfalanflufenamid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AA",
"display": "Nitrogen mustard analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AA10",
"display": "L01AA10"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-11-08T00:00:00Z",
"display": "2021-11-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AA10"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE01",
"display": "Imatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Imatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Imatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE01",
"display": "L01XE01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2007-03-04T00:00:00Z",
"display": "2007-03-04T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XY02",
"display": "Pertuzumab and trastuzumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pertuzumab and trastuzumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pertuzumab og trastuzumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XY",
"display": "Combinations of antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XY02",
"display": "L01XY02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-11-11T00:00:00Z",
"display": "2020-11-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XY02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01FX13",
"display": "Enfortumab vedotin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Enfortumab vedotin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Enfortumabvedotin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC36",
"display": "Enfortumab vedotin"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX13",
"display": "L01FX13"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX13"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01BC",
"display": "Pyrimidine analogues",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pyrimidine analogues"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pyrimidinanaloger"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01B",
"display": "Antimetabolites"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BC",
"display": "L01BC"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BC"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AA03",
"display": "Melphalan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Melphalan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Melfalan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AA",
"display": "Nitrogen mustard analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AA03",
"display": "L01AA03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AA03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XJ",
"display": "Hedgehog pathway inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Hedgehog pathway inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Hedgehog-signalvei hemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01X",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XJ",
"display": "L01XJ"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-13T00:00:00Z",
"display": "2020-10-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XJ"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX32",
"display": "Elranatamab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Elranatamab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Elranatamab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX32",
"display": "L01FX32"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-03-14T00:00:00Z",
"display": "2024-03-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX32"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE50",
"display": "Abemaciclib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Abemaciclib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Abemaciklib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE50",
"display": "L01XE50"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2018-07-11T00:00:00Z",
"display": "2018-07-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE50"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01BB04",
"display": "Cladribine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cladribine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kladribin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BB",
"display": "Purine analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BB04",
"display": "L01BB04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BB04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX01",
"display": "Edrecolomab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Edrecolomab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Edrekolomab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC01",
"display": "Edrecolomab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX01",
"display": "L01FX01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FA01",
"display": "Rituximab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Rituximab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Rituksimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FA",
"display": "CD20 (Clusters of differentitation 20) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC02",
"display": "Rituximab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FA01",
"display": "L01FA01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FA01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FY01",
"display": "Pertuzumab and trastuzumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pertuzumab and trastuzumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pertuzumab og trastuzumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FY",
"display": "Combinations of monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XY02",
"display": "Pertuzumab and trastuzumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FY01",
"display": "L01FY01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FY01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AG14",
"display": "Ublituximab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ublituximab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ublituksimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AG",
"display": "Monoclonal antibodies"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA57",
"display": "Ublituximab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AG14",
"display": "L04AG14"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-04-12T00:00:00Z",
"display": "2023-04-12T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AG14"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XJ03",
"display": "Glasdegib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Glasdegib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Glasdegib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XJ",
"display": "Hedgehog pathway inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX63",
"display": "Glasdegib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XJ03",
"display": "L01XJ03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XJ03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EL01",
"display": "Ibrutinibq",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ibrutinibq"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ibrutinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EL",
"display": "Bruton's tyrosine kinase (BTK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE27",
"display": "Ibrutinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EL01",
"display": "L01EL01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EL01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FC",
"display": "CD38 (Clusters of differentitation 38) inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "CD38 (Clusters of differentitation 38) inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "CD38 (Differensieringsantigen 38) hemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01F",
"display": "Monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FC",
"display": "L01FC"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-05-03T00:00:00Z",
"display": "2021-05-03T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FC"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01BB07",
"display": "Nelarabine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Nelarabine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Nelarabin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BB",
"display": "Purine analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BB07",
"display": "L01BB07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2007-03-04T00:00:00Z",
"display": "2007-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BB07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE14",
"display": "Bosutinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Bosutinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Bosutinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE14",
"display": "L01XE14"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2012-01-01T00:00:00Z",
"display": "2012-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE14"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EK",
"display": "Vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vaskulær endotel vekstfaktorreseptor (VEGFR) tyrosinkinasehemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01E",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EK",
"display": "L01EK"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-13T00:00:00Z",
"display": "2020-10-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EK"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01DB08",
"display": "Pirarubicin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pirarubicin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pirarubicin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01DB",
"display": "Anthracyclines and related substances"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01DB08",
"display": "L01DB08"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01DB08"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01ED03",
"display": "Alectinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Alectinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Alektinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01ED",
"display": "Anaplastic lymphoma kinase (ALK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE36",
"display": "Alectinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01ED03",
"display": "L01ED03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01ED03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AC25",
"display": "Levilimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Levilimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Levilimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC25",
"display": "L04AC25"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC25"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA56",
"display": "Deucravacitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Deucravacitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Deukravacitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA56",
"display": "L04AA56"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-11-08T00:00:00Z",
"display": "2021-11-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA56"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Other monoclonal antibodies and antibody drug conjugates"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Andre monoklonale antistoffer og antistoff-legemiddelkonjugater"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01F",
"display": "Monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX",
"display": "L01FX"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-05-03T00:00:00Z",
"display": "2021-05-03T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XD06",
"display": "Efaproxiral",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Efaproxiral"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Efaproksiral"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XD",
"display": "Sensitizers used in photodynamic/radiation therapy"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XD06",
"display": "L01XD06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2007-03-04T00:00:00Z",
"display": "2007-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XD06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC39",
"display": "Belantamab mafodotin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Belantamab mafodotin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Belantamabmafodotin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC39",
"display": "L01XC39"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-08-04T00:00:00Z",
"display": "2020-08-04T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC39"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AE",
"display": "Sphingosine-1-phosphate (S1P) receptor modulators",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sphingosine-1-phosphate (S1P) receptor modulators"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sfingosin-1-fosfat (S1P) reseptormodulatorer"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04A",
"display": "Immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AE",
"display": "L04AE"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-10-30T00:00:00Z",
"display": "2023-10-30T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AE"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC08",
"display": "Panitumumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Panitumumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Panitumumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC08",
"display": "L01XC08"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2006-05-08T00:00:00Z",
"display": "2006-05-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC08"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AA09",
"display": "Basiliximab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Basiliximab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Basiliksimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA09",
"display": "L04AA09"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA09"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AC15",
"display": "Sirukumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sirukumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sirukumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC15",
"display": "L04AC15"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2017-12-01T00:00:00Z",
"display": "2017-12-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC15"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AG12",
"display": "Ofatumumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ofatumumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ofatumumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AG",
"display": "Monoclonal antibodies"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA52",
"display": "Ofatumumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AG12",
"display": "L04AG12"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AG12"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX23",
"display": "Mitotane",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Mitotane"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Mitotan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX23",
"display": "L01XX23"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX23"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC33",
"display": "Cemiplimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cemiplimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Cemiplimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC33",
"display": "L01XC33"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-04-11T00:00:00Z",
"display": "2019-04-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC33"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01CA04",
"display": "Vinorelbine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vinorelbine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vinorelbin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01CA",
"display": "Vinca alkaloids and analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CA04",
"display": "L01CA04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CA04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AG16",
"display": "Rozanolixizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Rozanolixizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Rozanoliksizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AG",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AG16",
"display": "L04AG16"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-11-15T00:00:00Z",
"display": "2023-11-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AG16"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EK04",
"display": "Fruquintinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Fruquintinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Frukvintinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EK",
"display": "Vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EK04",
"display": "L01EK04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EK04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XM04",
"display": "Vorasidenib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vorasidenib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vorasidenib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XM",
"display": "Isocitrate dehydrogenase (IDH) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XM04",
"display": "L01XM04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-01-11T00:00:00Z",
"display": "2024-01-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XM04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE22",
"display": "Masitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Masitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Masitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE22",
"display": "L01XE22"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2012-10-03T00:00:00Z",
"display": "2012-10-03T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE22"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L03AA03",
"display": "Molgramostim",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Molgramostim"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Molgramostim"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AA",
"display": "Colony stimulating factors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AA03",
"display": "L03AA03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AA03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX07",
"display": "Cabozantinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cabozantinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kabozantinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE26",
"display": "Cabozantinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX07",
"display": "L01EX07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AX01",
"display": "Mitobronitol",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Mitobronitol"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Mitobronitol"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AX",
"display": "Other alkylating agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AX01",
"display": "L01AX01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AX01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AX23",
"display": "Motixafortide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Motixafortide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Motiksafortid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX23",
"display": "L03AX23"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2025-01-01T00:00:00Z",
"display": "2025-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX23"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02AE04",
"display": "Triptorelin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Triptorelin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Triptorelin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02AE",
"display": "Gonadotropin releasing hormone analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02AE04",
"display": "L02AE04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02AE04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX24",
"display": "Pegaspargase",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pegaspargase"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pegaspargase"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX24",
"display": "L01XX24"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX24"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX59",
"display": "Enasidenib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Enasidenib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Enasidenib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX59",
"display": "L01XX59"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2018-07-11T00:00:00Z",
"display": "2018-07-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2025-01-10T00:00:00Z",
"display": "2025-01-10T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX59"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EL04",
"display": "Orelabrutinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Orelabrutinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Orelabrutinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EL",
"display": "Bruton's tyrosine kinase (BTK) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EL04",
"display": "L01EL04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EL04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX58",
"display": "Epacadostat",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Epacadostat"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Epakadostat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX58",
"display": "L01XX58"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2018-07-11T00:00:00Z",
"display": "2018-07-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX58"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA22",
"display": "Abetimus",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Abetimus"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Abetimus"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA22",
"display": "L04AA22"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2006-08-09T00:00:00Z",
"display": "2006-08-09T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA22"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX21",
"display": "Tepotinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tepotinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tepotinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX21",
"display": "L01EX21"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-11-11T00:00:00Z",
"display": "2020-11-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX21"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02AE",
"display": "Gonadotropin releasing hormone analogues",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Gonadotropin releasing hormone analogues"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Gonadotropinfrigjørende hormonanaloger"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02A",
"display": "Hormones and related agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02AE",
"display": "L02AE"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02AE"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XM",
"display": "Isocitrate dehydrogenase (IDH) inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Isocitrate dehydrogenase (IDH) inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Isositratdehydrogenase (IDH) hemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01X",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XM",
"display": "L01XM"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-01-11T00:00:00Z",
"display": "2024-01-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XM"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AX09",
"display": "Diroximel fumarate",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Diroximel fumarate"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Diroksimelfumarat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AX",
"display": "Other immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AX09",
"display": "L04AX09"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-03-04T00:00:00Z",
"display": "2021-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AX09"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AF03",
"display": "Upadacitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Upadacitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Upadacitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AF",
"display": "Janus-associated kinase (JAK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA44",
"display": "Upadacitinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AF03",
"display": "L04AF03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AF03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX15",
"display": "Belantamab mafodotin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Belantamab mafodotin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Belantamabmafodotin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC39",
"display": "Belantamab mafodotin"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX15",
"display": "L01FX15"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX15"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XF02",
"display": "Alitretinoin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Alitretinoin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Alitretinoin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XF",
"display": "Retinoids for cancer treatment"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX22",
"display": "Alitretinoin"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XF02",
"display": "L01XF02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XF02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE02",
"display": "Gefitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Gefitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Gefitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE02",
"display": "L01XE02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2003-02-11T00:00:00Z",
"display": "2003-02-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XC05",
"display": "Gemtuzumab ozogamicin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Gemtuzumab ozogamicin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Gemtuzumabozogamicin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC05",
"display": "L01XC05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2006-01-03T00:00:00Z",
"display": "2006-01-03T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L03AB13",
"display": "Peginterferon beta-1a",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Peginterferon beta-1a"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Peginterferon beta-1a"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AB",
"display": "Interferons"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AB13",
"display": "L03AB13"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2014-02-20T00:00:00Z",
"display": "2014-02-20T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AB13"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AG17",
"display": "Seniprutug",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Seniprutug"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Seniprutug"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AG",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AG17",
"display": "L04AG17"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AG17"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AG01",
"display": "Muromonab-CD3",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Muromonab-CD3"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Muromonab-CD3"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AG",
"display": "Monoclonal antibodies"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA02",
"display": "Muromonab-CD3"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AG01",
"display": "L04AG01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AG01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02AE01",
"display": "Buserelin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Buserelin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Buserelin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02AE",
"display": "Gonadotropin releasing hormone analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02AE01",
"display": "L02AE01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02AE01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE03",
"display": "Erlotinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Erlotinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Erlotinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE03",
"display": "L01XE03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2007-03-04T00:00:00Z",
"display": "2007-03-04T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XX07",
"display": "Lonidamine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Lonidamine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Lonidamin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX07",
"display": "L01XX07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AX11",
"display": "Tasonermin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tasonermin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tasonermin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX11",
"display": "L03AX11"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX11"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA05",
"display": "Tacrolimus",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tacrolimus"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Takrolimus"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA05",
"display": "L04AA05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EE04",
"display": "Selumetinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Selumetinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Selumetinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EE",
"display": "Mitogen-activated protein kinase (MEK) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EE04",
"display": "L01EE04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-11-11T00:00:00Z",
"display": "2020-11-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EE04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC15",
"display": "Obinutuzumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Obinutuzumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Obinutuzumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC15",
"display": "L01XC15"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2013-12-10T00:00:00Z",
"display": "2013-12-10T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC15"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XY",
"display": "Combinations of antineoplastic agents",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Combinations of antineoplastic agents"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kombinasjoner av antineoplastiske midler"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01X",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XY",
"display": "L01XY"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XY"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX43",
"display": "Vismodegib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vismodegib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vismodegib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX43",
"display": "L01XX43"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2013-01-28T00:00:00Z",
"display": "2013-01-28T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX43"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EL03",
"display": "Zanubrutinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Zanubrutinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Zanubrutinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EL",
"display": "Bruton's tyrosine kinase (BTK) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EL03",
"display": "L01EL03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-11-11T00:00:00Z",
"display": "2020-11-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EL03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FD04",
"display": "Trastuzumab deruxtecan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Trastuzumab deruxtecan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Trastuzumabderukstekan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FD",
"display": "HER2 (Human epidermal growth factor receptor 2) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC41",
"display": "Trastuzumab deruxtecan"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FD04",
"display": "L01FD04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FD04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX03",
"display": "Altretamine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Altretamine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Altretamin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX03",
"display": "L01XX03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EN04",
"display": "Futibatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Futibatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Futibatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EN",
"display": "Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EN04",
"display": "L01EN04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-11-08T00:00:00Z",
"display": "2021-11-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EN04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA25",
"display": "Eculizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Eculizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ekulizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA25",
"display": "L04AA25"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA25"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L02BB05",
"display": "Apalutamide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Apalutamide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Apalutamid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BB",
"display": "Anti-androgens"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BB05",
"display": "L02BB05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2018-07-11T00:00:00Z",
"display": "2018-07-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BB05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FA02",
"display": "Ofatumumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ofatumumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ofatumumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FA",
"display": "CD20 (Clusters of differentitation 20) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC10",
"display": "Ofatumumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FA02",
"display": "L01FA02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-03T00:00:00Z",
"display": "2021-12-03T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FA02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AC03",
"display": "Carboquone",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Carboquone"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Karbokon"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AC",
"display": "Ethylene imines"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AC03",
"display": "L01AC03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AC03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX08",
"display": "Elotuzumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Elotuzumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Elotuzumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC23",
"display": "Elotuzumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX08",
"display": "L01FX08"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX08"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX29",
"display": "Talquetamab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Talquetamab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Talkvetamab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX29",
"display": "L01FX29"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-11-15T00:00:00Z",
"display": "2023-11-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX29"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01BA",
"display": "Folic acid analogues",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Folic acid analogues"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Folsyreanaloger"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01B",
"display": "Antimetabolites"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BA",
"display": "L01BA"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BA"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01CE01",
"display": "Topotecan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Topotecan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Topotekan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01CE",
"display": "Topoisomerase 1 inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX17",
"display": "Topotecan"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CE01",
"display": "L01CE01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CE01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX31",
"display": "Zolbetuximab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Zolbetuximab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Zolbetuksimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX31",
"display": "L01FX31"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-08-05T00:00:00Z",
"display": "2024-08-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX31"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX69",
"display": "Lurbinectedin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Lurbinectedin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Lurbinektedin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX69",
"display": "L01XX69"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-11-11T00:00:00Z",
"display": "2020-11-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX69"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX82",
"display": "Darinaparsin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Darinaparsin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Darinaparsin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX82",
"display": "L01XX82"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX82"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01E",
"display": "Protein kinase inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Protein kinase inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Proteinkinasehemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01",
"display": "Antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01E",
"display": "L01E"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-13T00:00:00Z",
"display": "2020-10-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01E"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX45",
"display": "Carfilzomib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Carfilzomib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Karfilzomib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX45",
"display": "L01XX45"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2013-12-10T00:00:00Z",
"display": "2013-12-10T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX45"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XX41",
"display": "Eribulin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Eribulin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Eribulin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX41",
"display": "L01XX41"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2011-01-01T00:00:00Z",
"display": "2011-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX41"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XL09",
"display": "Tabelecleucel",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tabelecleucel"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tabelekleucel"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XL",
"display": "Antineoplastic cell and gene therapy"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XL09",
"display": "L01XL09"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-12-22T00:00:00Z",
"display": "2022-12-22T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XL09"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX29",
"display": "Vimseltinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vimseltinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vimseltinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX29",
"display": "L01EX29"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2025-08-06T00:00:00Z",
"display": "2025-08-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX29"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AB04",
"display": "Adalimumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Adalimumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Adalimumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AB",
"display": "Tumor necrosis factor alpha (TNF-alpha) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA17",
"display": "Adalimumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AB04",
"display": "L04AB04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2003-09-15T00:00:00Z",
"display": "2003-09-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AB04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AJ10",
"display": "Vilobelimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vilobelimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vilobelimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AJ",
"display": "Complement inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AJ10",
"display": "L04AJ10"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AJ10"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA54",
"display": "Pegcetacoplan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pegcetacoplan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pegcetakoplan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA54",
"display": "L04AA54"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-11-08T00:00:00Z",
"display": "2021-11-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA54"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AC24",
"display": "Mirikizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Mirikizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Mirikizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC24",
"display": "L04AC24"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-10-02T00:00:00Z",
"display": "2023-10-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC24"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BB06",
"display": "Darolutamide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Darolutamide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Darolutamid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BB",
"display": "Anti-androgens"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BB06",
"display": "L02BB06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-04-11T00:00:00Z",
"display": "2019-04-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BB06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AF01",
"display": "Tofacitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tofacitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tofacitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AF",
"display": "Janus-associated kinase (JAK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA29",
"display": "Tofacitinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AF01",
"display": "L04AF01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AF01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX39",
"display": "Romidepsin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Romidepsin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Romidepsin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX39",
"display": "L01XX39"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2009-03-20T00:00:00Z",
"display": "2009-03-20T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX39"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01FX24",
"display": "Teclistamab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Teclistamab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Teklistamab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX24",
"display": "L01FX24"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-03-10T00:00:00Z",
"display": "2023-03-10T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX24"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FF07",
"display": "Dostarlimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Dostarlimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Dostarlimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FF",
"display": "PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) hemmere"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC40",
"display": "Dostarlimab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FF07",
"display": "L01FF07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FF07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EA",
"display": "BCR-ABL tyrosine kinase inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "BCR-ABL tyrosine kinase inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "BCR-ABL tyrosinkinasehemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01E",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EA",
"display": "L01EA"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-13T00:00:00Z",
"display": "2020-10-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EA"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XL05",
"display": "Ciltacabtagene autoleucel",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ciltacabtagene autoleucel"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ciltakabtagenautoleucel"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XL",
"display": "Antineoplastic cell and gene therapy"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XL05",
"display": "L01XL05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XL05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA35",
"display": "Begelomab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Begelomab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Begelomab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA35",
"display": "L04AA35"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2015-07-06T00:00:00Z",
"display": "2015-07-06T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA35"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EX28",
"display": "Repotrectinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Repotrectinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Repotrektinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX28",
"display": "L01EX28"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-01-03T00:00:00Z",
"display": "2024-01-03T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX28"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FF05",
"display": "Atezolizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Atezolizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Atezolizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FF",
"display": "PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) hemmere"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC32",
"display": "Atezolizumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FF05",
"display": "L01FF05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FF05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XB01",
"display": "Procarbazine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Procarbazine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Prokarbazin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XB",
"display": "Methylhydrazines"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XB01",
"display": "L01XB01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XB01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01DB",
"display": "Anthracyclines and related substances",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Anthracyclines and related substances"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Antracykliner og lignende substanser"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01D",
"display": "Cytotoxic antibiotics and related substances"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01DB",
"display": "L01DB"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01DB"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA43",
"display": "Ravulizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ravulizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ravulizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA43",
"display": "L04AA43"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-04-11T00:00:00Z",
"display": "2019-04-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA43"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EG",
"display": "Mammalian target of rapamycin (mTOR) kinase inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Mammalian target of rapamycin (mTOR) kinase inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "(mTOR) kinasehemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01E",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EG",
"display": "L01EG"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-13T00:00:00Z",
"display": "2020-10-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EG"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX27",
"display": "Capivasertib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Capivasertib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kapivasertib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX27",
"display": "L01EX27"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-11-15T00:00:00Z",
"display": "2023-11-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX27"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01CC01",
"display": "Demecolcine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Demecolcine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Demekolcin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01CC",
"display": "Colchicine derivatives"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CC01",
"display": "L01CC01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CC01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01D",
"display": "Cytotoxic antibiotics and related substances",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cytotoxic antibiotics and related substances"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Cytotoksiske antibiotika og lignende substanser"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01",
"display": "Antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01D",
"display": "L01D"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01D"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BB",
"display": "Anti-androgens",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Anti-androgens"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Antiandrogener"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02B",
"display": "Hormone antagonists and related agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BB",
"display": "L02BB"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BB"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01DC05",
"display": "Utidelone",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Utidelone"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Utidelon"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01DC",
"display": "Other cytotoxic antibiotics"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01DC05",
"display": "L01DC05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01DC05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AB03",
"display": "Mannosulfan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Mannosulfan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Mannosulfan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AB",
"display": "Alkyl sulfonates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AB03",
"display": "L01AB03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AB03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AH",
"display": "Mammalian target of rapamycin (mTOR) kinase inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Mammalian target of rapamycin (mTOR) kinase inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "(mTOR) kinasehemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04A",
"display": "Immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AH",
"display": "L04AH"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-10-30T00:00:00Z",
"display": "2023-10-30T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AH"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AG08",
"display": "Ocrelizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ocrelizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Okrelizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AG",
"display": "Monoclonal antibodies"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA36",
"display": "Ocrelizumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AG08",
"display": "L04AG08"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AG08"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX71",
"display": "Tisagenlecleucel",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tisagenlecleucel"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tisagenlekleucel"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX71",
"display": "L01XX71"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-01-21T00:00:00Z",
"display": "2020-01-21T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2023-01-13T00:00:00Z",
"display": "2023-01-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX71"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L03AX09",
"display": "Thymopentin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Thymopentin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tymopentin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX09",
"display": "L03AX09"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX09"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EA01",
"display": "Imatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Imatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Imatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EA",
"display": "BCR-ABL tyrosine kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE01",
"display": "Imatinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EA01",
"display": "L01EA01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EA01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AX17",
"display": "Sipuleucel-T",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sipuleucel-T"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sipuleucel-T"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX17",
"display": "L03AX17"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2012-01-01T00:00:00Z",
"display": "2012-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX17"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA60",
"display": "Remibrutinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Remibrutinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Remibrutinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA60",
"display": "L04AA60"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA60"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX44",
"display": "Aflibercept",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Aflibercept"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Aflibercept"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX44",
"display": "L01XX44"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2013-04-29T00:00:00Z",
"display": "2013-04-29T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX44"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AK01",
"display": "Leflunomide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Leflunomide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Leflunomid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AK",
"display": "Dihydroorotate dehydrogenase (DHODH) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA13",
"display": "Leflunomide"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AK01",
"display": "L04AK01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AK01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EB11",
"display": "Aumolertinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Aumolertinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Aumolertinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EB",
"display": "Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EB11",
"display": "L01EB11"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EB11"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EE02",
"display": "Cobimetinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cobimetinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kobimetinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EE",
"display": "Mitogen-activated protein kinase (MEK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE38",
"display": "Cobimetinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EE02",
"display": "L01EE02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EE02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC16",
"display": "Dinutuximab beta",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Dinutuximab beta"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Dinutuksimab beta"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC16",
"display": "L01XC16"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2014-01-06T00:00:00Z",
"display": "2014-01-06T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC16"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01FF06",
"display": "Cemiplimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cemiplimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Cemiplimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FF",
"display": "PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) hemmere"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC33",
"display": "Cemiplimab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FF06",
"display": "L01FF06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FF06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01CD01",
"display": "Paclitaxel",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Paclitaxel"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Paklitaksel"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01CD",
"display": "Taxanes"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CD01",
"display": "L01CD01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CD01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX38",
"display": "Vorinostat",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vorinostat"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vorinostat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX38",
"display": "L01XX38"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2009-03-20T00:00:00Z",
"display": "2009-03-20T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX38"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01CE03",
"display": "Etirinotecan pegol",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Etirinotecan pegol"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Etirinotekan pegol"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01CE",
"display": "Topoisomerase 1 inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX56",
"display": "Etirinotecan pegol"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CE03",
"display": "L01CE03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CE03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AX05",
"display": "Pidotimod",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pidotimod"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pidotimod"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX05",
"display": "L03AX05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01CA02",
"display": "Vincristine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vincristine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vinkristin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01CA",
"display": "Vinca alkaloids and analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CA02",
"display": "L01CA02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CA02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03",
"display": "Immunostimulants",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Immunostimulants"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Immunstimulerende midler"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L",
"display": "Antineoplastic and immunomodulating agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03",
"display": "L03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AA01",
"display": "Cyclophosphamide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cyclophosphamide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Syklofosfamid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AA",
"display": "Nitrogen mustard analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AA01",
"display": "L01AA01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AA01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE40",
"display": "Olmutinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Olmutinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Olmutinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE40",
"display": "L01XE40"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2016-12-20T00:00:00Z",
"display": "2016-12-20T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE40"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EB03",
"display": "Afatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Afatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Afatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EB",
"display": "Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE13",
"display": "Afatinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EB03",
"display": "L01EB03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EB03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE44",
"display": "Lorlatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Lorlatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Lorlatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE44",
"display": "L01XE44"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2018-07-11T00:00:00Z",
"display": "2018-07-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE44"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EX03",
"display": "Pazopanib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pazopanib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pazopanib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE11",
"display": "Pazopanib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX03",
"display": "L01EX03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA18",
"display": "Everolimus",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Everolimus"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Everolimus"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA18",
"display": "L04AA18"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2003-08-22T00:00:00Z",
"display": "2003-08-22T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA18"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EG02",
"display": "Everolimus",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Everolimus"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Everolimus"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EG",
"display": "Mammalian target of rapamycin (mTOR) kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE10",
"display": "Everolimus"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EG02",
"display": "L01EG02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EG02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XA05",
"display": "Polyplatillen",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Polyplatillen"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Polyplatillen"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XA",
"display": "Platinum compounds"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XA05",
"display": "L01XA05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2011-01-01T00:00:00Z",
"display": "2011-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XA05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA06",
"display": "Mycophenolic acid",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Mycophenolic acid"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Mykofenolsyre"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA06",
"display": "L04AA06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01DB06",
"display": "Idarubicin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Idarubicin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Idarubicin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01DB",
"display": "Anthracyclines and related substances"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01DB06",
"display": "L01DB06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01DB06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE56",
"display": "Entrectinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Entrectinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Entrektinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE56",
"display": "L01XE56"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-12-16T00:00:00Z",
"display": "2019-12-16T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE56"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XX60",
"display": "Talazoparib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Talazoparib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Talazoparib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX60",
"display": "L01XX60"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2018-05-04T00:00:00Z",
"display": "2018-05-04T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX60"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EL02",
"display": "Acalabrutinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Acalabrutinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Akalabrutinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EL",
"display": "Bruton's tyrosine kinase (BTK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE51",
"display": "Acalabrutinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EL02",
"display": "L01EL02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EL02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AX12",
"display": "Melanoma vaccine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Melanoma vaccine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Melanomvaksine"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX12",
"display": "L03AX12"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX12"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC34",
"display": "Moxetumomab pasudotox",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Moxetumomab pasudotox"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Moksetumomabpasudotoks"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC34",
"display": "L01XC34"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-12T00:00:00Z",
"display": "2020-10-12T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC34"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XE48",
"display": "Icotinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Icotinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ikotinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE48",
"display": "L01XE48"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2018-07-11T00:00:00Z",
"display": "2018-07-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE48"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L03AX04",
"display": "Pegademase",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pegademase"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pegademase"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX04",
"display": "L03AX04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC13",
"display": "Pertuzumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pertuzumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pertuzumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC13",
"display": "L01XC13"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2013-01-28T00:00:00Z",
"display": "2013-01-28T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC13"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XG",
"display": "Proteasome inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Proteasome inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Proteasomhemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01X",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XG",
"display": "L01XG"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-13T00:00:00Z",
"display": "2020-10-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XG"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FF01",
"display": "Nivolumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Nivolumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Nivolumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FF",
"display": "PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) hemmere"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC17",
"display": "Nivolumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FF01",
"display": "L01FF01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FF01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AC13",
"display": "Ixekizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ixekizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Iksekizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC13",
"display": "L04AC13"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2016-02-10T00:00:00Z",
"display": "2016-02-10T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC13"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AC03",
"display": "Anakinra",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Anakinra"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Anakinra"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA14",
"display": "Anakinra"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC03",
"display": "L04AC03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA57",
"display": "Ublituximab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ublituximab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ublituksimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA57",
"display": "L04AA57"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-01T00:00:00Z",
"display": "2024-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA57"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XE",
"display": "Protein kinase inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Protein kinase inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Proteinkinasehemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01X",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE",
"display": "L01XE"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2007-03-04T00:00:00Z",
"display": "2007-03-04T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-01-15T00:00:00Z",
"display": "2021-01-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XE31",
"display": "Nintedanib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Nintedanib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Nintedanib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE31",
"display": "L01XE31"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2014-12-04T00:00:00Z",
"display": "2014-12-04T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE31"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01F",
"display": "Monoclonal antibodies and antibody drug conjugates",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Monoclonal antibodies and antibody drug conjugates"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Monoklonale antistoffer og antistoff-legemiddelkonjugater"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01",
"display": "Antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01F",
"display": "L01F"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-05-03T00:00:00Z",
"display": "2021-05-03T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01F"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BB02",
"display": "Nilutamide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Nilutamide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Nilutamid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BB",
"display": "Anti-androgens"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BB02",
"display": "L02BB02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BB02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XL01",
"display": "Sitimagene ceradenovec",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sitimagene ceradenovec"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sitimagenceradenovek"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XL",
"display": "Antineoplastic cell and gene therapy"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX37",
"display": "Sitimagene ceradenovec"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XL01",
"display": "L01XL01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-09-09T00:00:00Z",
"display": "2022-09-09T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XL01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AG06",
"display": "Alemtuzumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Alemtuzumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Alemtuzumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AG",
"display": "Monoclonal antibodies"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA34",
"display": "Alemtuzumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AG06",
"display": "L04AG06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AG06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA02",
"display": "Muromonab-CD3",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Muromonab-CD3"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Muromonab-CD3"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA02",
"display": "L04AA02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EF02",
"display": "Ribociclib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ribociclib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ribosiklib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EF",
"display": "Cyclin-dependent kinases (CDK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE42",
"display": "Ribociclib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EF02",
"display": "L01EF02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EF02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX02",
"display": "Sorafenib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sorafenib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sorafenib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE05",
"display": "Sorafenib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX02",
"display": "L01EX02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX17",
"display": "Sacituzumab govitecan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sacituzumab govitecan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sacituzumabgovitekan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX17",
"display": "L01FX17"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-10-26T00:00:00Z",
"display": "2021-10-26T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX17"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FE01",
"display": "Cetuximab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cetuximab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Cetuksimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FE",
"display": "EGFR (Epidermal growth factor receptor) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC06",
"display": "Cetuximab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FE01",
"display": "L01FE01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FE01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AA18",
"display": "Efbemalenograstim alfa",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Efbemalenograstim alfa"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Efbemalenograstim alfa"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AA",
"display": "Colony stimulating factors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AA18",
"display": "L03AA18"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AA18"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AC04",
"display": "Rilonacept",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Rilonacept"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Rilonacept"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC04",
"display": "L04AC04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2009-03-23T00:00:00Z",
"display": "2009-03-23T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX06",
"display": "Dinutuximab beta",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Dinutuximab beta"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Dinutuksimab beta"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC16",
"display": "Dinutuximab beta"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX06",
"display": "L01FX06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE16",
"display": "Crizotinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Crizotinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Krizotinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE16",
"display": "L01XE16"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2012-01-01T00:00:00Z",
"display": "2012-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE16"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01DA01",
"display": "Dactinomycin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Dactinomycin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Daktinomycin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01DA",
"display": "Actinomycines"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01DA01",
"display": "L01DA01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01DA01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01DB05",
"display": "Zorubicin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Zorubicin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Zorubicin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01DB",
"display": "Anthracyclines and related substances"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01DB05",
"display": "L01DB05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01DB05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EM03",
"display": "Alpelisib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Alpelisib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Alpelisib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EM",
"display": "Phosphatidylinositol-3-kinase (Pi3K) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX65",
"display": "Alpelisib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EM03",
"display": "L01EM03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EM03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AD",
"display": "Calcineurin inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Calcineurin inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kalsineurinhemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04A",
"display": "Immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AD",
"display": "L04AD"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AD"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01BB03",
"display": "Tioguanine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tioguanine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tioguanin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BB",
"display": "Purine analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BB03",
"display": "L01BB03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BB03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AB09",
"display": "Interferon alfacon-1",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Interferon alfacon-1"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Interferon alfakon-1"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AB",
"display": "Interferons"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AB09",
"display": "L03AB09"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AB09"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AA17",
"display": "Pegteograstim",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pegteograstim"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pegteograstim"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AA",
"display": "Colony stimulating factors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AA17",
"display": "L03AA17"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2017-01-11T00:00:00Z",
"display": "2017-01-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AA17"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02AE51",
"display": "Leuprorelin and bicalutamide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Leuprorelin and bicalutamide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Leuprorelin og bikalutamid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02AE",
"display": "Gonadotropin releasing hormone analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02AE51",
"display": "L02AE51"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2018-07-11T00:00:00Z",
"display": "2018-07-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02AE51"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC",
"display": "Monoclonal antibodies",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Monoclonal antibodies"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Monoklonale antistoffer"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01X",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC",
"display": "L01XC"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-19T00:00:00Z",
"display": "2022-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EX05",
"display": "Regorafenib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Regorafenib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Regorafenib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE21",
"display": "Regorafenib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX05",
"display": "L01EX05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AG03",
"display": "Natalizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Natalizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Natalizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AG",
"display": "Monoclonal antibodies"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA23",
"display": "Natalizumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AG03",
"display": "L04AG03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AG03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC17",
"display": "Nivolumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Nivolumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Nivolumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC17",
"display": "L01XC17"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2015-01-22T00:00:00Z",
"display": "2015-01-22T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC17"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XX14",
"display": "Tretinoin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tretinoin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tretinoin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX14",
"display": "L01XX14"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX14"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01FX18",
"display": "Amivantamab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Amivantamab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Amivantamab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX18",
"display": "L01FX18"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-11-01T00:00:00Z",
"display": "2021-11-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX18"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XK05",
"display": "Veliparib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Veliparib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Veliparib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XK",
"display": "Poly (ADP-ribose) polymerase (PARP) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XK05",
"display": "L01XK05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-11-11T00:00:00Z",
"display": "2020-11-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XK05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE17",
"display": "Axitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Axitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Aksitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE17",
"display": "L01XE17"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2012-01-01T00:00:00Z",
"display": "2012-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE17"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EB08",
"display": "Icotinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Icotinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ikotinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EB",
"display": "Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE48",
"display": "Icotinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EB08",
"display": "L01EB08"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EB08"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE37",
"display": "Rociletinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Rociletinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Rociletinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE37",
"display": "L01XE37"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2016-02-09T00:00:00Z",
"display": "2016-02-09T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE37"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XX65",
"display": "Alpelisib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Alpelisib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Alpelisib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX65",
"display": "L01XX65"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-12-16T00:00:00Z",
"display": "2019-12-16T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX65"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XC18",
"display": "Pembrolizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pembrolizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pembrolizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC18",
"display": "L01XC18"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2014-10-01T00:00:00Z",
"display": "2014-10-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC18"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L03AX24",
"display": "Mavorixafor",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Mavorixafor"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Mavoriksafor"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX24",
"display": "L03AX24"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2025-01-01T00:00:00Z",
"display": "2025-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX24"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EJ04",
"display": "Momelotinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Momelotinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Momelotinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EJ",
"display": "Janus-associated kinase (JAK) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EJ04",
"display": "L01EJ04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EJ04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE51",
"display": "Acalabrutinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Acalabrutinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Akalabrutinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE51",
"display": "L01XE51"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-04-11T00:00:00Z",
"display": "2019-04-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE51"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XX49",
"display": "Belinostat",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Belinostat"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Belinostat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX49",
"display": "L01XX49"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2015-01-22T00:00:00Z",
"display": "2015-01-22T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX49"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EB09",
"display": "Lazertinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Lazertinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Lazertinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EB",
"display": "Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EB09",
"display": "L01EB09"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-05T00:00:00Z",
"display": "2022-05-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EB09"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AC",
"display": "Interleukin inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Interleukin inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Interleukinhemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04A",
"display": "Immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC",
"display": "L04AC"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XD03",
"display": "Methyl aminolevulinate",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Methyl aminolevulinate"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Metylaminolevulinat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XD",
"display": "Sensitizers used in photodynamic/radiation therapy"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XD03",
"display": "L01XD03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2006-05-31T00:00:00Z",
"display": "2006-05-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XD03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FE02",
"display": "Panitumumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Panitumumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Panitumumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FE",
"display": "EGFR (Epidermal growth factor receptor) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC08",
"display": "Panitumumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FE02",
"display": "L01FE02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FE02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AX07",
"display": "Dimethyl fumarate",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Dimethyl fumarate"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Dimetylfumarat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AX",
"display": "Other immunosuppressants"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/f7949a93-d26e-4235-ac5d-d2b898a7aad4",
"code": "N07XX09",
"display": "Dimethyl fumarate"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AX07",
"display": "L04AX07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2018-12-20T00:00:00Z",
"display": "2018-12-20T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AX07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FD",
"display": "HER2 (Human epidermal growth factor receptor 2) inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "HER2 (Human epidermal growth factor receptor 2) inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "HER2 (Epidermal vekstfaktorreseptor 2, human) hemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01F",
"display": "Monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FD",
"display": "L01FD"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-05-03T00:00:00Z",
"display": "2021-05-03T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FD"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX51",
"display": "Talimogene laherparepvec",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Talimogene laherparepvec"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Talimogenlaherparepvek"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX51",
"display": "L01XX51"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2016-02-10T00:00:00Z",
"display": "2016-02-10T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2023-01-13T00:00:00Z",
"display": "2023-01-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX51"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XC36",
"display": "Enfortumab vedotin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Enfortumab vedotin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Enfortumabvedotin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC36",
"display": "L01XC36"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-11-11T00:00:00Z",
"display": "2020-11-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC36"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L02AE03",
"display": "Goserelin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Goserelin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Goserelin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02AE",
"display": "Gonadotropin releasing hormone analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02AE03",
"display": "L02AE03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02AE03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02",
"display": "Endocrine therapy",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Endocrine therapy"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Endokrin terapi"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L",
"display": "Antineoplastic and immunomodulating agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02",
"display": "L02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AB10",
"display": "Peginterferon alfa-2b",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Peginterferon alfa-2b"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Peginterferon alfa-2b"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AB",
"display": "Interferons"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AB10",
"display": "L03AB10"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AB10"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XJ01",
"display": "Vismodegib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vismodegib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vismodegib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XJ",
"display": "Hedgehog pathway inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX43",
"display": "Vismodegib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XJ01",
"display": "L01XJ01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XJ01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AA09",
"display": "Bendamustine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Bendamustine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Bendamustin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AA",
"display": "Nitrogen mustard analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AA09",
"display": "L01AA09"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2010-01-01T00:00:00Z",
"display": "2010-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AA09"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE10",
"display": "Everolimus",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Everolimus"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Everolimus"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE10",
"display": "L01XE10"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2010-01-01T00:00:00Z",
"display": "2010-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE10"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L02BG03",
"display": "Anastrozole",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Anastrozole"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Anastrozol"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BG",
"display": "Aromatase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BG03",
"display": "L02BG03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BG03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC11",
"display": "Ipilimumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ipilimumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ipilimumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC11",
"display": "L01XC11"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2011-09-22T00:00:00Z",
"display": "2011-09-22T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC11"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AC10",
"display": "Secukinumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Secukinumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sekukinumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC10",
"display": "L04AC10"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2012-01-01T00:00:00Z",
"display": "2012-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC10"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01B",
"display": "Antimetabolites",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Antimetabolites"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Antimetabolitter"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01",
"display": "Antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01B",
"display": "L01B"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01B"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XH",
"display": "Histone deacetylase (HDAC) inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Histone deacetylase (HDAC) inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Histondeacetylasehemmere (HDAC)"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01X",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XH",
"display": "L01XH"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-13T00:00:00Z",
"display": "2020-10-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XH"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA61",
"display": "Nerandomilast",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Nerandomilast"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Nerandomilast"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA61",
"display": "L04AA61"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2025-04-30T00:00:00Z",
"display": "2025-04-30T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA61"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent (internt)",
"display": "Godkjent (internt)"
}
}
]
},
{
"code": "L01BC59",
"display": "Trifluridine, combinations",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Trifluridine, combinations"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Trifluridin, kombinasjoner"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BC",
"display": "Pyrimidine analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BC59",
"display": "L01BC59"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2014-07-15T00:00:00Z",
"display": "2014-07-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BC59"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA",
"display": "Selective immunosuppressants",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Selective immunosuppressants"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Selektive immunsuppressive midler"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04A",
"display": "Immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA",
"display": "L04AA"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AJ04",
"display": "Sutimlimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sutimlimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sutimlimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AJ",
"display": "Complement inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA55",
"display": "Sutimlimab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AJ04",
"display": "L04AJ04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AJ04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XA03",
"display": "Oxaliplatin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Oxaliplatin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Oksaliplatin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XA",
"display": "Platinum compounds"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XA03",
"display": "L01XA03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XA03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XL",
"display": "Antineoplastic cell and gene therapy",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Antineoplastic cell and gene therapy"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Antineoplastisk celle- og genterapi"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01X",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XL",
"display": "L01XL"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XL"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX08",
"display": "Pentostatin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pentostatin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pentostatin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX08",
"display": "L01XX08"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX08"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AK02",
"display": "Teriflunomide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Teriflunomide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Teriflunomid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AK",
"display": "Dihydroorotate dehydrogenase (DHODH) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA31",
"display": "Teriflunomide"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AK02",
"display": "L04AK02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AK02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AC11",
"display": "Siltuximab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Siltuximab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Siltuksimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC11",
"display": "L04AC11"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2014-05-12T00:00:00Z",
"display": "2014-05-12T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC11"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX68",
"display": "Belotecan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Belotecan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Belotekan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX68",
"display": "L01XX68"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-12-16T00:00:00Z",
"display": "2019-12-16T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX68"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01AB01",
"display": "Busulfan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Busulfan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Busulfan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AB",
"display": "Alkyl sulfonates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AB01",
"display": "L01AB01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AB01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX36",
"display": "Patritumab deruxtecan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Patritumab deruxtecan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Patritumabderukstekan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX36",
"display": "L01FX36"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX36"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX78",
"display": "Navitoclax",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Navitoclax"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Navitoklaks"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX78",
"display": "L01XX78"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-11-15T00:00:00Z",
"display": "2023-11-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX78"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AC",
"display": "Interleukins",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Interleukins"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Interleukiner"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03A",
"display": "Immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AC",
"display": "L03AC"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AC"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AX02",
"display": "Roquinimex",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Roquinimex"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Rokinimeks"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX02",
"display": "L03AX02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA10",
"display": "Sirolimus",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sirolimus"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sirolimus"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA10",
"display": "L04AA10"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA10"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L02B",
"display": "Hormone antagonists and related agents",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Hormone antagonists and related agents"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Hormonantagonister og beslektede substanser"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02",
"display": "Endocrine therapy"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02B",
"display": "L02B"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02B"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01BC53",
"display": "Tegafur, combinations",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tegafur, combinations"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tegafur, kombinasjoner"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BC",
"display": "Pyrimidine analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BC53",
"display": "L01BC53"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2007-03-04T00:00:00Z",
"display": "2007-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BC53"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AX02",
"display": "Pipobroman",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pipobroman"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pipobroman"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AX",
"display": "Other alkylating agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AX02",
"display": "L01AX02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AX02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FF09",
"display": "Tislelizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tislelizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tislelizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FF",
"display": "PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) hemmere"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FF09",
"display": "L01FF09"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-11-08T00:00:00Z",
"display": "2021-11-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FF09"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AC22",
"display": "Spesolimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Spesolimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Spesolimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC22",
"display": "L04AC22"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-11-08T00:00:00Z",
"display": "2021-11-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC22"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AD04",
"display": "Streptozocin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Streptozocin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Streptozocin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AD",
"display": "Nitrosoureas"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AD04",
"display": "L01AD04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AD04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC19",
"display": "Blinatumomab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Blinatumomab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Blinatumomab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC19",
"display": "L01XC19"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2015-01-22T00:00:00Z",
"display": "2015-01-22T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC19"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01FF11",
"display": "Sugemalimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sugemalimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sugemalimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FF",
"display": "PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) hemmere"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FF11",
"display": "L01FF11"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FF11"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AA06",
"display": "Ifosfamide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ifosfamide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ifosfamid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AA",
"display": "Nitrogen mustard analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AA06",
"display": "L01AA06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AA06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01CC",
"display": "Colchicine derivatives",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Colchicine derivatives"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kolkisinderivater"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01C",
"display": "Plant alkaloids and other natural products"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CC",
"display": "L01CC"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CC"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02AA02",
"display": "Polyestradiol phosphate",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Polyestradiol phosphate"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Polyøstradiolfosfat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02AA",
"display": "Estrogens"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02AA02",
"display": "L02AA02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02AA02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AA16",
"display": "Empegfilgrastim",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Empegfilgrastim"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Empegfilgrastim"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AA",
"display": "Colony stimulating factors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AA16",
"display": "L03AA16"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2016-02-09T00:00:00Z",
"display": "2016-02-09T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AA16"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AC05",
"display": "Ustekinumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ustekinumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ustekinumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC05",
"display": "L04AC05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2009-03-23T00:00:00Z",
"display": "2009-03-23T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XY01",
"display": "Cytarabine and daunorubicin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cytarabine and daunorubicin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Cytarabin og daunorubicin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XY",
"display": "Combinations of antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XY01",
"display": "L01XY01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2018-07-11T00:00:00Z",
"display": "2018-07-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XY01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX19",
"display": "Irinotecan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Irinotecan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Irinotekan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX19",
"display": "L01XX19"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX19"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01FE",
"display": "EGFR (Epidermal growth factor receptor) inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "EGFR (Epidermal growth factor receptor) inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "EGFR (Epidermal vekstfaktorreseptor) hemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01F",
"display": "Monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FE",
"display": "L01FE"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-05-03T00:00:00Z",
"display": "2021-05-03T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FE"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EJ01",
"display": "Ruxolitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ruxolitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ruksolitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EJ",
"display": "Janus-associated kinase (JAK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE18",
"display": "Ruxolitinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EJ01",
"display": "L01EJ01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EJ01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FF03",
"display": "Durvalumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Durvalumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Durvalumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FF",
"display": "PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) hemmere"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC28",
"display": "Durvalumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FF03",
"display": "L01FF03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FF03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AG",
"display": "Epoxides",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Epoxides"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Epoksider"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01A",
"display": "Alkylating agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AG",
"display": "L01AG"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AG"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EF",
"display": "Cyclin-dependent kinases (CDK) inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cyclin-dependent kinases (CDK) inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Cyklinavhengige kinasehemmere (CDK)"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01E",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EF",
"display": "L01EF"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-13T00:00:00Z",
"display": "2020-10-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EF"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AE05",
"display": "Etrasimod",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Etrasimod"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Etrasimod"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AE",
"display": "Sphingosine-1-phosphate (S1P) receptor modulators"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AE05",
"display": "L04AE05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-11-15T00:00:00Z",
"display": "2023-11-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AE05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX20",
"display": "Pemigatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pemigatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pemigatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX20",
"display": "L01EX20"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-11-11T00:00:00Z",
"display": "2020-11-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX20"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01FX07",
"display": "Blinatumomab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Blinatumomab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Blinatumomab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC19",
"display": "Blinatumomab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX07",
"display": "L01FX07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AG15",
"display": "Divozilimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Divozilimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Divozilimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AG",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AG15",
"display": "L04AG15"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AG15"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE12",
"display": "Vandetanib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vandetanib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vandetanib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE12",
"display": "L01XE12"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2011-01-01T00:00:00Z",
"display": "2011-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE12"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EX09",
"display": "Nintedanib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Nintedanib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Nintedanib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE31",
"display": "Nintedanib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX09",
"display": "L01EX09"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX09"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AB02",
"display": "Infliximab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Infliximab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Infliksimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AB",
"display": "Tumor necrosis factor alpha (TNF-alpha) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA12",
"display": "Infliximab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AB02",
"display": "L04AB02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AB02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AD01",
"display": "Ciclosporin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ciclosporin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ciklosporin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AD",
"display": "Calcineurin inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA01",
"display": "Ciclosporin"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AD01",
"display": "L04AD01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AD01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX61",
"display": "Copanlisib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Copanlisib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kopanlisib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX61",
"display": "L01XX61"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2018-07-11T00:00:00Z",
"display": "2018-07-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX61"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01DB07",
"display": "Mitoxantrone",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Mitoxantrone"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Mitoksantron"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01DB",
"display": "Anthracyclines and related substances"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01DB07",
"display": "L01DB07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01DB07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EB10",
"display": "Mobocertinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Mobocertinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Mobosertinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EB",
"display": "Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EB10",
"display": "L01EB10"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EB10"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AA",
"display": "Colony stimulating factors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Colony stimulating factors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kolonistimulerende midler"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03A",
"display": "Immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AA",
"display": "L03AA"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AA"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX34",
"display": "Odronextamab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Odronextamab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Odronekstamab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX34",
"display": "L01FX34"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX34"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AJ07",
"display": "Crovalimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Crovalimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Krovalimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AJ",
"display": "Complement inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AJ07",
"display": "L04AJ07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-11-15T00:00:00Z",
"display": "2023-11-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AJ07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AF04",
"display": "Filgotinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Filgotinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Filgotinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AF",
"display": "Janus-associated kinase (JAK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA45",
"display": "Filgotinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AF04",
"display": "L04AF04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AF04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01X",
"display": "Other antineoplastic agents",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Other antineoplastic agents"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Andre antineoplastiske midler"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01",
"display": "Antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01X",
"display": "L01X"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01X"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX33",
"display": "Tarlatamab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tarlatamab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tarlatamab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX33",
"display": "L01FX33"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX33"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01C",
"display": "Plant alkaloids and other natural products",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Plant alkaloids and other natural products"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Plantealkaloider og andre naturprodukter"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01",
"display": "Antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01C",
"display": "L01C"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01C"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EM01",
"display": "Idelalisib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Idelalisib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Idelalisib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EM",
"display": "Phosphatidylinositol-3-kinase (Pi3K) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX47",
"display": "Idelalisib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EM01",
"display": "L01EM01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EM01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX26",
"display": "Sitravatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sitravatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sitravatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX26",
"display": "L01EX26"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-11-15T00:00:00Z",
"display": "2023-11-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX26"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AF06",
"display": "Peficitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Peficitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Peficitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AF",
"display": "Janus-associated kinase (JAK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA49",
"display": "Peficitinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AF06",
"display": "L04AF06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AF06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX52",
"display": "Venetoclax",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Venetoclax"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Venetoklaks"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX52",
"display": "L01XX52"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2015-11-21T00:00:00Z",
"display": "2015-11-21T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX52"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA45",
"display": "Filgotinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Filgotinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Filgotinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA45",
"display": "L04AA45"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-04T00:00:00Z",
"display": "2020-10-04T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA45"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L02AE05",
"display": "Histrelin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Histrelin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Histrelin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02AE",
"display": "Gonadotropin releasing hormone analogues"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/bd343711-ab45-4ebd-9f2c-b128f422645e",
"code": "H01CA03",
"display": "Histrelin"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02AE05",
"display": "L02AE05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2012-12-21T00:00:00Z",
"display": "2012-12-21T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02AE05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AG07",
"display": "Begelomab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Begelomab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Begelomab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AG",
"display": "Monoclonal antibodies"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA35",
"display": "Begelomab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AG07",
"display": "L04AG07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AG07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AJ03",
"display": "Pegcetacoplan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pegcetacoplan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pegcetakoplan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AJ",
"display": "Complement inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA54",
"display": "Pegcetacoplan"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AJ03",
"display": "L04AJ03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AJ03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AB06",
"display": "Interferon alfa-n1",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Interferon alfa-n1"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Interferon alfa-n1"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AB",
"display": "Interferons"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AB06",
"display": "L03AB06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AB06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX17",
"display": "Topotecan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Topotecan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Topotekan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX17",
"display": "L01XX17"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX17"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01FF13",
"display": "Toripalimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Toripalimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Toripalimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FF",
"display": "PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) hemmere"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FF13",
"display": "L01FF13"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-11-15T00:00:00Z",
"display": "2023-11-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FF13"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01BC05",
"display": "Gemcitabine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Gemcitabine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Gemcitabin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BC",
"display": "Pyrimidine analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BC05",
"display": "L01BC05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BC05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EC",
"display": "B-Raf serine-threonine kinase (BRAF) inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "B-Raf serine-threonine kinase (BRAF) inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "B-Raf serin-treoninkinasehemmere (BRAF)"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01E",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EC",
"display": "L01EC"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-13T00:00:00Z",
"display": "2020-10-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EC"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FF10",
"display": "Retifanlimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Retifanlimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Retifanlimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FF",
"display": "PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) hemmere"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FF10",
"display": "L01FF10"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-11-08T00:00:00Z",
"display": "2021-11-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FF10"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EL05",
"display": "Pirtobrutinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pirtobrutinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pirtobrutinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EL",
"display": "Bruton's tyrosine kinase (BTK) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EL05",
"display": "L01EL05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EL05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC03",
"display": "Trastuzumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Trastuzumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Trastuzumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC03",
"display": "L01XC03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EE",
"display": "Mitogen-activated protein kinase (MEK) inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Mitogen-activated protein kinase (MEK) inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Mitogenaktiverte proteinkinasehemmere (MEK)"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01E",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EE",
"display": "L01EE"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-13T00:00:00Z",
"display": "2020-10-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EE"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AA12",
"display": "Ancestim",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ancestim"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ancestim"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AA",
"display": "Colony stimulating factors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AA12",
"display": "L03AA12"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AA12"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX73",
"display": "Sotorasib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sotorasib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sotorasib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX73",
"display": "L01XX73"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-03-04T00:00:00Z",
"display": "2021-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX73"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX57",
"display": "Plitidepsin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Plitidepsin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Plitidepsin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX57",
"display": "L01XX57"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2017-01-11T00:00:00Z",
"display": "2017-01-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX57"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA12",
"display": "Infliximab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Infliximab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Infliksimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA12",
"display": "L04AA12"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA12"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L03AX21",
"display": "Elapegademase",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Elapegademase"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Elapegademase"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX21",
"display": "L03AX21"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-08-20T00:00:00Z",
"display": "2020-08-20T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX21"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX74",
"display": "Belzutifan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Belzutifan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Belzutifan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX74",
"display": "L01XX74"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-11-08T00:00:00Z",
"display": "2021-11-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX74"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EL",
"display": "Bruton's tyrosine kinase (BTK) inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Bruton's tyrosine kinase (BTK) inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Brutons tyrosinkinasehemmere (BTK)"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01E",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EL",
"display": "L01EL"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-13T00:00:00Z",
"display": "2020-10-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EL"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA34",
"display": "Alemtuzumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Alemtuzumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Alemtuzumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC04",
"display": "Alemtuzumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA34",
"display": "L04AA34"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2015-01-01T00:00:00Z",
"display": "2015-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA34"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AC09",
"display": "Briakinumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Briakinumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Briakinumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC09",
"display": "L04AC09"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2010-10-12T00:00:00Z",
"display": "2010-10-12T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC09"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX16",
"display": "Mitoguazone",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Mitoguazone"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Mitoguazon"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX16",
"display": "L01XX16"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX16"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX37",
"display": "Sitimagene ceradenovec",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sitimagene ceradenovec"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sitimagenseradenovek"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX37",
"display": "L01XX37"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2023-01-13T00:00:00Z",
"display": "2023-01-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX37"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AA16",
"display": "Afelimomab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Afelimomab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Afelimomab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA16",
"display": "L04AA16"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2007-03-04T00:00:00Z",
"display": "2007-03-04T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA16"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L03AX",
"display": "Other immunostimulants",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Other immunostimulants"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Andre immunstimulerende midler"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03A",
"display": "Immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX",
"display": "L03AX"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EA04",
"display": "Bosutinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Bosutinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Bosutinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EA",
"display": "BCR-ABL tyrosine kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE14",
"display": "Bosutinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EA04",
"display": "L01EA04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EA04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA29",
"display": "Tofacitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tofacitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tofacitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA29",
"display": "L04AA29"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2013-01-29T00:00:00Z",
"display": "2013-01-29T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA29"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01DC03",
"display": "Mitomycin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Mitomycin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Mitomycin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01DC",
"display": "Other cytotoxic antibiotics"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01DC03",
"display": "L01DC03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01DC03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX80",
"display": "Imetelstat",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Imetelstat"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Imetelstat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX80",
"display": "L01XX80"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-11-15T00:00:00Z",
"display": "2023-11-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX80"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FD06",
"display": "Margetuximab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Margetuximab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Margetuksimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FD",
"display": "HER2 (Human epidermal growth factor receptor 2) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FD06",
"display": "L01FD06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FD06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XL11",
"display": "Lifileucel",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Lifileucel"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Lifileucel"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XL",
"display": "Antineoplastic cell and gene therapy"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XL11",
"display": "L01XL11"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-11-15T00:00:00Z",
"display": "2023-11-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XL11"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XH07",
"display": "Resminostat",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Resminostat"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Resminostat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XH",
"display": "Histone deacetylase (HDAC) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XH07",
"display": "L01XH07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XH07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BA03",
"display": "Fulvestrant",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Fulvestrant"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Fulvestrant"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BA",
"display": "Anti-estrogens"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BA03",
"display": "L02BA03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2003-03-12T00:00:00Z",
"display": "2003-03-12T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BA03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EH02",
"display": "Neratinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Neratinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Neratinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EH",
"display": "Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE45",
"display": "Neratinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EH02",
"display": "L01EH02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EH02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX48",
"display": "Sonidegib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sonidegib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sonidegib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX48",
"display": "L01XX48"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2015-01-22T00:00:00Z",
"display": "2015-01-22T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX48"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01FF12",
"display": "Serplulimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Serplulimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Serplulimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FF",
"display": "PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) hemmere"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FF12",
"display": "L01FF12"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FF12"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AJ06",
"display": "Zilucoplan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Zilucoplan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Zilukoplan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AJ",
"display": "Complement inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AJ06",
"display": "L04AJ06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AJ06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FC02",
"display": "Isatuximab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Isatuximab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Isatuksimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FC",
"display": "CD38 (Clusters of differentitation 38) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC38",
"display": "Isatuximab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FC02",
"display": "L01FC02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FC02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX32",
"display": "Bortezomib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Bortezomib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Bortezomib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX32",
"display": "L01XX32"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2004-07-01T00:00:00Z",
"display": "2004-07-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX32"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01BC06",
"display": "Capecitabine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Capecitabine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kapecitabin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BC",
"display": "Pyrimidine analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BC06",
"display": "L01BC06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BC06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AJ05",
"display": "Avacopan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Avacopan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Avakopan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AJ",
"display": "Complement inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA59",
"display": "Avacopan"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AJ05",
"display": "L04AJ05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AJ05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AB",
"display": "Tumor necrosis factor alpha (TNF-alpha) inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tumor necrosis factor alpha (TNF-alpha) inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tumornekrosefaktor alfa (TNF-alfa)-hemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04A",
"display": "Immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AB",
"display": "L04AB"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AB"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AB16",
"display": "Peginterferon alfacon-2",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Peginterferon alfacon-2"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Peginterferon alfakon-2"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AB",
"display": "Interferons"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AB16",
"display": "L03AB16"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-11-08T00:00:00Z",
"display": "2021-11-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AB16"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE09",
"display": "Temsirolimus",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Temsirolimus"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Temsirolimus"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE09",
"display": "L01XE09"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2008-05-22T00:00:00Z",
"display": "2008-05-22T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE09"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AC12",
"display": "Brodalumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Brodalumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Brodalumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC12",
"display": "L04AC12"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2015-07-06T00:00:00Z",
"display": "2015-07-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC12"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01CE04",
"display": "Belotecan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Belotecan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Belotekan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01CE",
"display": "Topoisomerase 1 inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX68",
"display": "Belotecan"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CE04",
"display": "L01CE04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CE04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX11",
"display": "Bermekimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Bermekimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Bermekimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC29",
"display": "Bermekimab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX11",
"display": "L01FX11"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX11"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX01",
"display": "Amsacrine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Amsacrine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Amsakrin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX01",
"display": "L01XX01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XA01",
"display": "Cisplatin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cisplatin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Cisplatin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XA",
"display": "Platinum compounds"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XA01",
"display": "L01XA01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XA01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02AE02",
"display": "Leuprorelin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Leuprorelin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Leuprorelin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02AE",
"display": "Gonadotropin releasing hormone analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02AE02",
"display": "L02AE02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02AE02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX24",
"display": "Surufatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Surufatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Surufatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX24",
"display": "L01EX24"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX24"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01BC04",
"display": "Carmofur",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Carmofur"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Karmofur"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BC",
"display": "Pyrimidine analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BC04",
"display": "L01BC04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BC04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EN01",
"display": "Erdafitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Erdafitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Erdafitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EN",
"display": "Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX16",
"display": "Erdafitinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EN01",
"display": "L01EN01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-04-07T00:00:00Z",
"display": "2022-04-07T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EN01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE11",
"display": "Pazopanib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pazopanib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pazopanib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE11",
"display": "L01XE11"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2010-01-01T00:00:00Z",
"display": "2010-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE11"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EX14",
"display": "Entrectinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Entrectinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Entrektinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE56",
"display": "Entrectinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX14",
"display": "L01EX14"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX14"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01DC",
"display": "Other cytotoxic antibiotics",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Other cytotoxic antibiotics"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Andre cytotoksiske antibiotika"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01D",
"display": "Cytotoxic antibiotics and related substances"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01DC",
"display": "L01DC"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01DC"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01BA03",
"display": "Raltitrexed",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Raltitrexed"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Raltitreksed"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BA",
"display": "Folic acid analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BA03",
"display": "L01BA03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BA03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA24",
"display": "Abatacept",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Abatacept"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Abatacept"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA24",
"display": "L04AA24"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2007-01-01T00:00:00Z",
"display": "2007-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA24"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EA05",
"display": "Ponatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ponatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ponatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EA",
"display": "BCR-ABL tyrosine kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE24",
"display": "Ponatinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EA05",
"display": "L01EA05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EA05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EM",
"display": "Phosphatidylinositol-3-kinase (Pi3K) inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Phosphatidylinositol-3-kinase (Pi3K) inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Fosfatidylinositol-3-kinasehemmere (Pi3K)"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01E",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EM",
"display": "L01EM"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-13T00:00:00Z",
"display": "2020-10-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EM"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX23",
"display": "Pralsetinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pralsetinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pralsetinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX23",
"display": "L01EX23"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-03-04T00:00:00Z",
"display": "2021-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX23"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC02",
"display": "Rituximab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Rituximab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Rituksimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC02",
"display": "L01XC02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L03AB07",
"display": "Interferon beta-1a",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Interferon beta-1a"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Interferon beta-1a"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AB",
"display": "Interferons"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AB07",
"display": "L03AB07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AB07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EH03",
"display": "Tucatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tucatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tukatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EH",
"display": "Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EH03",
"display": "L01EH03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-11-11T00:00:00Z",
"display": "2020-11-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EH03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AG13",
"display": "Teprotumumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Teprotumumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Teprotumumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AG",
"display": "Monoclonal antibodies"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA53",
"display": "Teprotumumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AG13",
"display": "L04AG13"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AG13"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX08",
"display": "Lenvatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Lenvatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Lenvatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE29",
"display": "Lenvatinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX08",
"display": "L01EX08"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX08"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01DB04",
"display": "Aclarubicin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Aclarubicin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Aklarubicin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01DB",
"display": "Anthracyclines and related substances"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01DB04",
"display": "L01DB04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01DB04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01CA03",
"display": "Vindesine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vindesine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vindesin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01CA",
"display": "Vinca alkaloids and analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CA03",
"display": "L01CA03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CA03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX19",
"display": "Ripretinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ripretinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ripretinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX19",
"display": "L01EX19"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-11-11T00:00:00Z",
"display": "2020-11-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX19"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC41",
"display": "Trastuzumab deruxtecan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Trastuzumab deruxtecan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Trastuzumabderukstekan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC41",
"display": "L01XC41"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-11-11T00:00:00Z",
"display": "2020-11-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC41"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AJ02",
"display": "Ravulizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ravulizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ravulizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AJ",
"display": "Complement inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA43",
"display": "Ravulizumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AJ02",
"display": "L04AJ02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AJ02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC23",
"display": "Elotuzumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Elotuzumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Elotuzumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC23",
"display": "L01XC23"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2016-02-09T00:00:00Z",
"display": "2016-02-09T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC23"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XE07",
"display": "Lapatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Lapatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Lapatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE07",
"display": "L01XE07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L02BX",
"display": "Other hormone antagonists and related agents",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Other hormone antagonists and related agents"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Andre hormonantagonister og beslektede substanser"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02B",
"display": "Hormone antagonists and related agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BX",
"display": "L02BX"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2007-03-04T00:00:00Z",
"display": "2007-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BX"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EJ",
"display": "Janus-associated kinase (JAK) inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Janus-associated kinase (JAK) inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Janus-assosierte kinasehemmere (JAK)"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01E",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EJ",
"display": "L01EJ"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-13T00:00:00Z",
"display": "2020-10-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EJ"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA15",
"display": "Alefacept",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Alefacept"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Alefacept"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA15",
"display": "L04AA15"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2007-03-04T00:00:00Z",
"display": "2007-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA15"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC24",
"display": "Daratumumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Daratumumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Daratumumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC24",
"display": "L01XC24"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2016-02-09T00:00:00Z",
"display": "2016-02-09T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC24"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XC27",
"display": "Olaratumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Olaratumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Olaratumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC27",
"display": "L01XC27"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2016-09-26T00:00:00Z",
"display": "2016-09-26T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC27"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01FB02",
"display": "Moxetumomab pasudotox",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Moxetumomab pasudotox"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Moksetumomabpasudotoks"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FB",
"display": "CD22 (Clusters of differentitation 22) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC34",
"display": "Moxetumomab pasudotox"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FB02",
"display": "L01FB02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FB02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XA02",
"display": "Carboplatin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Carboplatin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Karboplatin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XA",
"display": "Platinum compounds"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XA02",
"display": "L01XA02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XA02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01CA05",
"display": "Vinflunine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vinflunine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vinflunin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01CA",
"display": "Vinca alkaloids and analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CA05",
"display": "L01CA05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2010-01-01T00:00:00Z",
"display": "2010-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CA05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01CX",
"display": "Other plant alkaloids and natural products",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Other plant alkaloids and natural products"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Andre plantealkaloider og naturprodukter"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01C",
"display": "Plant alkaloids and other natural products"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CX",
"display": "L01CX"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2007-03-04T00:00:00Z",
"display": "2007-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CX"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01CD03",
"display": "Paclitaxel poliglumex",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Paclitaxel poliglumex"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Paklitakselpoliglumeks"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01CD",
"display": "Taxanes"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CD03",
"display": "L01CD03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2009-03-20T00:00:00Z",
"display": "2009-03-20T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CD03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX53",
"display": "Vosaroxin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vosaroxin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vosaroksin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX53",
"display": "L01XX53"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2016-12-20T00:00:00Z",
"display": "2016-12-20T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX53"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AX18",
"display": "Cridanimod",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cridanimod"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kridanimod"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX18",
"display": "L03AX18"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2013-12-10T00:00:00Z",
"display": "2013-12-10T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX18"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BA04",
"display": "Elacestrant",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Elacestrant"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Elacestrant"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BA",
"display": "Anti-estrogens"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BA04",
"display": "L02BA04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BA04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA14",
"display": "Anakinra",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Anakinra"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Anakinra"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA14",
"display": "L04AA14"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2003-02-12T00:00:00Z",
"display": "2003-02-12T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA14"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L03AX07",
"display": "Poly I:C",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Poly I:C"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Poly I:C"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX07",
"display": "L03AX07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX25",
"display": "Umbralisib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Umbralisib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Umbralisib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX25",
"display": "L01EX25"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX25"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XH01",
"display": "Vorinostat",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vorinostat"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vorinostat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XH",
"display": "Histone deacetylase (HDAC) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX38",
"display": "Vorinostat"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XH01",
"display": "L01XH01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XH01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA42",
"display": "Siponimod",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Siponimod"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Siponimod"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA42",
"display": "L04AA42"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-04-11T00:00:00Z",
"display": "2019-04-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA42"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AA39",
"display": "Emapalumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Emapalumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Emapalumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA39",
"display": "L04AA39"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2018-07-11T00:00:00Z",
"display": "2018-07-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA39"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01AX",
"display": "Other alkylating agents",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Other alkylating agents"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Andre alkyleringsmidler"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01A",
"display": "Alkylating agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AX",
"display": "L01AX"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AX"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FF08",
"display": "Prolgolimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Prolgolimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Prolgolimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FF",
"display": "PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) hemmere"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC42",
"display": "Prolgolimab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FF08",
"display": "L01FF08"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FF08"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XA",
"display": "Platinum compounds",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Platinum compounds"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Platinaforbindelser"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01X",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XA",
"display": "L01XA"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XA"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01DB09",
"display": "Valrubicin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Valrubicin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Valrubicin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01DB",
"display": "Anthracyclines and related substances"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01DB09",
"display": "L01DB09"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01DB09"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX63",
"display": "Glasdegib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Glasdegib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Glasdegib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX63",
"display": "L01XX63"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-04-11T00:00:00Z",
"display": "2019-04-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX63"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01AX03",
"display": "Temozolomide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Temozolomide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Temozolomid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AX",
"display": "Other alkylating agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AX03",
"display": "L01AX03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AX03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XA04",
"display": "Satraplatin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Satraplatin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Satraplatin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XA",
"display": "Platinum compounds"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XA04",
"display": "L01XA04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2009-03-20T00:00:00Z",
"display": "2009-03-20T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XA04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA48",
"display": "Belumosudil",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Belumosudil"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Belumosudil"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA48",
"display": "L04AA48"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-03-04T00:00:00Z",
"display": "2021-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA48"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FF",
"display": "PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) hemmere",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) hemmere"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "PD-1/PDL-1 (Programmert celledødprotein 1/celledødligand 1) hemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01F",
"display": "Monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FF",
"display": "L01FF"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-05-03T00:00:00Z",
"display": "2021-05-03T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FF"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX23",
"display": "Tisotumab vedotin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tisotumab vedotin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tisotumabvedotin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX23",
"display": "L01FX23"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX23"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX47",
"display": "Idelalisib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Idelalisib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Idelalisib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX47",
"display": "L01XX47"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2014-02-20T00:00:00Z",
"display": "2014-02-20T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX47"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01BB",
"display": "Purine analogues",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Purine analogues"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Purinanaloger"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01B",
"display": "Antimetabolites"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BB",
"display": "L01BB"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BB"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AG11",
"display": "Anifrolumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Anifrolumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Anifrolumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AG",
"display": "Monoclonal antibodies"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA51",
"display": "Anifrolumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AG11",
"display": "L04AG11"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AG11"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AC16",
"display": "Guselkumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Guselkumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Guselkumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC16",
"display": "L04AC16"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2017-09-28T00:00:00Z",
"display": "2017-09-28T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC16"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA51",
"display": "Anifrolumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Anifrolumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Anifrolumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA51",
"display": "L04AA51"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-03-04T00:00:00Z",
"display": "2021-03-04T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA51"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XD05",
"display": "Temoporfin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Temoporfin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Temoporfin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XD",
"display": "Sensitizers used in photodynamic/radiation therapy"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XD05",
"display": "L01XD05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2004-04-13T00:00:00Z",
"display": "2004-04-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XD05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AC07",
"display": "Tocilizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tocilizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tocilizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC07",
"display": "L04AC07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2009-03-23T00:00:00Z",
"display": "2009-03-23T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BG01",
"display": "Aminogluthetimide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Aminogluthetimide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Aminoglutetimid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BG",
"display": "Aromatase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BG01",
"display": "L02BG01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BG01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01CD",
"display": "Taxanes",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Taxanes"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Taksaner"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01C",
"display": "Plant alkaloids and other natural products"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CD",
"display": "L01CD"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CD"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX04",
"display": "Vandetanib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vandetanib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vandetanib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE12",
"display": "Vandetanib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX04",
"display": "L01EX04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01BA01",
"display": "Methotrexate",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Methotrexate"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Metotreksat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BA",
"display": "Folic acid analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BA01",
"display": "L01BA01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BA01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC10",
"display": "Ofatumumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ofatumumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ofatumumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC10",
"display": "L01XC10"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2010-01-01T00:00:00Z",
"display": "2010-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC10"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XE53",
"display": "Larotrectinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Larotrectinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Larotrektinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE53",
"display": "L01XE53"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-04-11T00:00:00Z",
"display": "2019-04-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE53"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01DB10",
"display": "Amrubicin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Amrubicin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Amrubicin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01DB",
"display": "Anthracyclines and related substances"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01DB10",
"display": "L01DB10"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2011-01-01T00:00:00Z",
"display": "2011-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01DB10"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA31",
"display": "Teriflunomide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Teriflunomide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Teriflunomid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA31",
"display": "L04AA31"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2013-10-01T00:00:00Z",
"display": "2013-10-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA31"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01CB01",
"display": "Etoposide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Etoposide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Etoposid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01CB",
"display": "Podophyllotoxin derivatives"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CB01",
"display": "L01CB01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CB01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BA",
"display": "Anti-estrogens",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Anti-estrogens"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Antiøstrogener"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02B",
"display": "Hormone antagonists and related agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BA",
"display": "L02BA"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BA"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EG01",
"display": "Temsirolimus",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Temsirolimus"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Temsirolimus"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EG",
"display": "Mammalian target of rapamycin (mTOR) kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE09",
"display": "Temsirolimus"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EG01",
"display": "L01EG01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EG01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA41",
"display": "Imlifidase",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Imlifidase"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Imlifidase"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA41",
"display": "L04AA41"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-04-11T00:00:00Z",
"display": "2019-04-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA41"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AB05",
"display": "Certolizumab pegol",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Certolizumab pegol"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Certolizumab pegol"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AB",
"display": "Tumor necrosis factor alpha (TNF-alpha) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AB05",
"display": "L04AB05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AB05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE28",
"display": "Ceritinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ceritinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ceritinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE28",
"display": "L01XE28"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2014-07-15T00:00:00Z",
"display": "2014-07-15T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE28"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XE18",
"display": "Ruxolitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ruxolitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ruksolitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE18",
"display": "L01XE18"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2012-01-01T00:00:00Z",
"display": "2012-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE18"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01BA04",
"display": "Pemetrexed",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pemetrexed"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pemetreksed"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BA",
"display": "Folic acid analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BA04",
"display": "L01BA04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2004-10-18T00:00:00Z",
"display": "2004-10-18T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BA04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX55",
"display": "Rucaparib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Rucaparib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Rukaparib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX55",
"display": "L01XX55"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2017-01-11T00:00:00Z",
"display": "2017-01-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX55"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01CA06",
"display": "Vintafolide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vintafolide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vintafolid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01CA",
"display": "Vinca alkaloids and analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CA06",
"display": "L01CA06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2013-12-10T00:00:00Z",
"display": "2013-12-10T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CA06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01CE",
"display": "Topoisomerase 1 inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Topoisomerase 1 inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Topoisomerase 1 hemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01C",
"display": "Plant alkaloids and other natural products"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CE",
"display": "L01CE"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-13T00:00:00Z",
"display": "2020-10-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CE"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AG09",
"display": "Emapalumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Emapalumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Emapalumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AG",
"display": "Monoclonal antibodies"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA39",
"display": "Emapalumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AG09",
"display": "L04AG09"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AG09"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FG01",
"display": "Bevacizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Bevacizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Bevacizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FG",
"display": "VEGF/VEGFR (Vascular endothelial growth factor) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC07",
"display": "Bevacizumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FG01",
"display": "L01FG01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FG01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02AA03",
"display": "Ethinylestradiol",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ethinylestradiol"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Etinyløstradiol"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02AA",
"display": "Estrogens"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02AA03",
"display": "L02AA03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02AA03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EK01",
"display": "Axitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Axitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Aksitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EK",
"display": "Vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE17",
"display": "Axitinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EK01",
"display": "L01EK01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EK01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AC02",
"display": "Basiliximab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Basiliximab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Basiliksimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA09",
"display": "Basiliximab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC02",
"display": "L04AC02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AC19",
"display": "Satralizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Satralizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Satralizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC19",
"display": "L04AC19"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-11-11T00:00:00Z",
"display": "2020-11-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC19"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EA06",
"display": "Asciminib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Asciminib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Askiminib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EA",
"display": "BCR-ABL tyrosine kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EA06",
"display": "L01EA06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-03-04T00:00:00Z",
"display": "2021-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EA06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EL06",
"display": "Tirabrutinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tirabrutinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tirabrutinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EL",
"display": "Bruton's tyrosine kinase (BTK) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EL06",
"display": "L01EL06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2025-01-01T00:00:00Z",
"display": "2025-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EL06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EF03",
"display": "Abemaciclib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Abemaciclib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Abemaciklib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EF",
"display": "Cyclin-dependent kinases (CDK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE50",
"display": "Abemaciclib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EF03",
"display": "L01EF03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EF03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX01",
"display": "Sunitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sunitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sunitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE04",
"display": "Sunitinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX01",
"display": "L01EX01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01ED05",
"display": "Lorlatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Lorlatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Lorlatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01ED",
"display": "Anaplastic lymphoma kinase (ALK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE44",
"display": "Lorlatinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01ED05",
"display": "L01ED05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01ED05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XG03",
"display": "Ixazomib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ixazomib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Iksazomib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XG",
"display": "Proteasome inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX50",
"display": "Ixazomib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XG03",
"display": "L01XG03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XG03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE57",
"display": "Fedratinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Fedratinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Fedratinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE57",
"display": "L01XE57"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2019-12-16T00:00:00Z",
"display": "2019-12-16T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE57"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01FB01",
"display": "Inotuzumab ozogamicin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Inotuzumab ozogamicin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Inotuzumabozogamicin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FB",
"display": "CD22 (Clusters of differentitation 22) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC26",
"display": "Inotuzumab ozogamicin"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FB01",
"display": "L01FB01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FB01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EB05",
"display": "Rociletinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Rociletinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Rosiletinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EB",
"display": "Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE37",
"display": "Rociletinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EB05",
"display": "L01EB05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EB05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX33",
"display": "Celecoxib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Celecoxib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Celekoksib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX33",
"display": "L01XX33"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2003-11-25T00:00:00Z",
"display": "2003-11-25T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX33"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE05",
"display": "Sorafenib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sorafenib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sorafenib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE05",
"display": "L01XE05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2007-01-01T00:00:00Z",
"display": "2007-01-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AA50",
"display": "Ponesimod",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ponesimod"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ponesimod"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA50",
"display": "L04AA50"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-03-04T00:00:00Z",
"display": "2021-03-04T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA50"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XL02",
"display": "Talimogene laherparepvec",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Talimogene laherparepvec"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Talimogenlaherparepvek"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XL",
"display": "Antineoplastic cell and gene therapy"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX51",
"display": "Talimogene laherparepvec"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XL02",
"display": "L01XL02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-09-09T00:00:00Z",
"display": "2022-09-09T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XL02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FA03",
"display": "Obinutuzumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Obinutuzumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Obinutuzumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FA",
"display": "CD20 (Clusters of differentitation 20) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC15",
"display": "Obinutuzumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FA03",
"display": "L01FA03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FA03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FE03",
"display": "Necitumumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Necitumumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Necitumumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FE",
"display": "EGFR (Epidermal growth factor receptor) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC22",
"display": "Necitumumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FE03",
"display": "L01FE03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FE03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EH",
"display": "Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Human epidermal vekstfaktorreseptor 2 (HER2) tyrosinkinasehemmere"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01E",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EH",
"display": "L01EH"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-13T00:00:00Z",
"display": "2020-10-13T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EH"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EJ02",
"display": "Fedratinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Fedratinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Fedratinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EJ",
"display": "Janus-associated kinase (JAK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE57",
"display": "Fedratinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EJ02",
"display": "L01EJ02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EJ02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX83",
"display": "Para-toluenesulfonamide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Para-toluenesulfonamide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Para-toluensulfonamid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX83",
"display": "L01XX83"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX83"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BG06",
"display": "Exemestane",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Exemestane"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Eksemestan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BG",
"display": "Aromatase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BG06",
"display": "L02BG06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BG06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AD07",
"display": "Ranimustine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ranimustine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ranimustin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AD",
"display": "Nitrosoureas"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AD07",
"display": "L01AD07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AD07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01BB05",
"display": "Fludarabine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Fludarabine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Fludarabin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BB",
"display": "Purine analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BB05",
"display": "L01BB05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BB05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EN02",
"display": "Pemigatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pemigatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pemigatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EN",
"display": "Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX20",
"display": "Pemigatinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EN02",
"display": "L01EN02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EN02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX05",
"display": "Brentuximab vedotin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Brentuximab vedotin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Brentuksimabvedotin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC12",
"display": "Brentuximab vedotin"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX05",
"display": "L01FX05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX09",
"display": "Mogamulizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Mogamulizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Mogamulizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC25",
"display": "Mogamulizumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX09",
"display": "L01FX09"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-12-02T00:00:00Z",
"display": "2021-12-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX09"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC29",
"display": "Bermekimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Bermekimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Bermekimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC29",
"display": "L01XC29"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2017-12-01T00:00:00Z",
"display": "2017-12-01T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC29"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01CX01",
"display": "Trabectedin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Trabectedin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Trabektedin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01CX",
"display": "Other plant alkaloids and natural products"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CX01",
"display": "L01CX01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2007-03-04T00:00:00Z",
"display": "2007-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CX01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AX01",
"display": "Lentinan",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Lentinan"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Lentinan"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX01",
"display": "L03AX01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AA10",
"display": "Lenograstim",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Lenograstim"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Lenograstim"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AA",
"display": "Colony stimulating factors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AA10",
"display": "L03AA10"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AA10"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FD05",
"display": "Trastuzumab duocarmazine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Trastuzumab duocarmazine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Trastuzumabduokarmazin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FD",
"display": "HER2 (Human epidermal growth factor receptor 2) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FD05",
"display": "L01FD05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-11-08T00:00:00Z",
"display": "2021-11-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FD05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AF05",
"display": "Itacitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Itacitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Itakitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AF",
"display": "Janus-associated kinase (JAK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA46",
"display": "Itacitinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AF05",
"display": "L04AF05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AF05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AB12",
"display": "Albinterferon alfa-2b",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Albinterferon alfa-2b"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Albinterferon alfa-2b"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AB",
"display": "Interferons"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AB12",
"display": "L03AB12"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2011-01-01T00:00:00Z",
"display": "2011-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AB12"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA47",
"display": "Inebilizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Inebilizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Inebilizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA47",
"display": "L04AA47"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-11-11T00:00:00Z",
"display": "2020-11-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA47"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XL07",
"display": "Idecabtagene vicleucel",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Idecabtagene vicleucel"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Idekabtagenvikleucel"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XL",
"display": "Antineoplastic cell and gene therapy"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XL07",
"display": "L01XL07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XL07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AG02",
"display": "Efalizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Efalizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Efalizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AG",
"display": "Monoclonal antibodies"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA21",
"display": "Efalizumab"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AG02",
"display": "L04AG02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AG02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AX08",
"display": "Poly ICLC",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Poly ICLC"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Poly ICLC"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX08",
"display": "L03AX08"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX08"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FY03",
"display": "Prolgolimab and nurulimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Prolgolimab and nurulimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Prolgolimab og nurulimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FY",
"display": "Combinations of monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FY03",
"display": "L01FY03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-11-15T00:00:00Z",
"display": "2023-11-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FY03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AA07",
"display": "Trofosfamide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Trofosfamide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Trofosfamid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AA",
"display": "Nitrogen mustard analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AA07",
"display": "L01AA07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AA07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA58",
"display": "Efgartigimod alfa",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Efgartigimod alfa"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Efgartigimod alfa"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA58",
"display": "L04AA58"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA58"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX50",
"display": "Ixazomib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ixazomib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Iksazomib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX50",
"display": "L01XX50"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2015-07-06T00:00:00Z",
"display": "2015-07-06T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX50"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01DB03",
"display": "Epirubicin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Epirubicin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Epirubicin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01DB",
"display": "Anthracyclines and related substances"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01DB03",
"display": "L01DB03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01DB03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AB08",
"display": "Interferon beta-1b",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Interferon beta-1b"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Interferon beta-1b"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AB",
"display": "Interferons"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AB08",
"display": "L03AB08"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AB08"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01CD51",
"display": "Paclitaxel and encequidar",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Paclitaxel and encequidar"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Paklitaksel og encekidar"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01CD",
"display": "Taxanes"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01CD51",
"display": "L01CD51"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-05T00:00:00Z",
"display": "2022-05-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01CD51"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BB01",
"display": "Flutamide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Flutamide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Flutamid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BB",
"display": "Anti-androgens"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BB01",
"display": "L02BB01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BB01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04A",
"display": "Immunosuppressants",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Immunosuppressants"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Immunsuppressive midler"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04",
"display": "Immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04A",
"display": "L04A"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04A"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX40",
"display": "Omacetaxine mepesuccinate",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Omacetaxine mepesuccinate"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Omacetaksinmepesuksinat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX40",
"display": "L01XX40"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2009-12-14T00:00:00Z",
"display": "2009-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX40"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BG05",
"display": "Vorozole",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Vorozole"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Vorozol"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BG",
"display": "Aromatase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BG05",
"display": "L02BG05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BG05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA52",
"display": "Ofatumumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ofatumumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ofatumumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA52",
"display": "L04AA52"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-03-04T00:00:00Z",
"display": "2021-03-04T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA52"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XX79",
"display": "Eflornithine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Eflornithine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Eflornitin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX79",
"display": "L01XX79"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-11-15T00:00:00Z",
"display": "2023-11-15T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX79"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX84",
"display": "Pelabresib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pelabresib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pelabresib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX84",
"display": "L01XX84"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX84"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX81",
"display": "Nirogacestat",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Nirogacestat"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Nirogacestat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX81",
"display": "L01XX81"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2024-11-19T00:00:00Z",
"display": "2024-11-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX81"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AF",
"display": "Janus-associated kinase (JAK) inhibitors",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Janus-associated kinase (JAK) inhibitors"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Janus-assosierte kinasehemmere (JAK)"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04A",
"display": "Immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AF",
"display": "L04AF"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-10-30T00:00:00Z",
"display": "2023-10-30T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AF"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AD06",
"display": "Nimustine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Nimustine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Nimustin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AD",
"display": "Nitrosoureas"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AD06",
"display": "L01AD06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AD06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XG01",
"display": "Bortezomib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Bortezomib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Bortezomib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XG",
"display": "Proteasome inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX32",
"display": "Bortezomib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XG01",
"display": "L01XG01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XG01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AH02",
"display": "Everolimus",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Everolimus"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Everolimus"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AH",
"display": "Mammalian target of rapamycin (mTOR) kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA18",
"display": "Everolimus"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AH02",
"display": "L04AH02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AH02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AC17",
"display": "Tildrakizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tildrakizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tildrakizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC17",
"display": "L04AC17"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2018-07-11T00:00:00Z",
"display": "2018-07-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC17"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XB",
"display": "Methylhydrazines",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Methylhydrazines"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Metylhydraziner"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01X",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XB",
"display": "L01XB"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XB"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EB02",
"display": "Erlotinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Erlotinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Erlotinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EB",
"display": "Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE03",
"display": "Erlotinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EB02",
"display": "L01EB02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EB02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01BC09",
"display": "Floxuridine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Floxuridine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Floksuridin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BC",
"display": "Pyrimidine analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BC09",
"display": "L01BC09"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2018-07-11T00:00:00Z",
"display": "2018-07-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BC09"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AD03",
"display": "Voclosporin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Voclosporin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Voklosporin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AD",
"display": "Calcineurin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AD03",
"display": "L04AD03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2011-01-01T00:00:00Z",
"display": "2011-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AD03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE46",
"display": "Encorafenib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Encorafenib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Enkorafenib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE46",
"display": "L01XE46"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2018-07-11T00:00:00Z",
"display": "2018-07-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE46"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AC21",
"display": "Bimekizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Bimekizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Bimekizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC21",
"display": "L04AC21"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-03-04T00:00:00Z",
"display": "2021-03-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC21"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EC03",
"display": "Encorafenib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Encorafenib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Enkorafenib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EC",
"display": "B-Raf serine-threonine kinase (BRAF) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE46",
"display": "Encorafenib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EC03",
"display": "L01EC03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EC03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XK52",
"display": "Niraparib and abiraterone",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Niraparib and abiraterone"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Niraparib og abirateron"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XK",
"display": "Poly (ADP-ribose) polymerase (PARP) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XK52",
"display": "L01XK52"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-08-21T00:00:00Z",
"display": "2023-08-21T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XK52"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA55",
"display": "Sutimlimab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sutimlimab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sutimlimab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA55",
"display": "L04AA55"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-11-08T00:00:00Z",
"display": "2021-11-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2024-01-19T00:00:00Z",
"display": "2024-01-19T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA55"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01EX16",
"display": "Erdafitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Erdafitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Erdafitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX16",
"display": "L01EX16"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-11-11T00:00:00Z",
"display": "2020-11-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX16"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XK03",
"display": "Rucaparib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Rucaparib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Rukaparib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XK",
"display": "Poly (ADP-ribose) polymerase (PARP) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX55",
"display": "Rucaparib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XK03",
"display": "L01XK03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XK03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XC26",
"display": "Inotuzumab ozogamicin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Inotuzumab ozogamicin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Inotuzumabozogamicin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XC",
"display": "Monoclonal antibodies"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XC26",
"display": "L01XC26"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2016-02-09T00:00:00Z",
"display": "2016-02-09T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2022-01-31T00:00:00Z",
"display": "2022-01-31T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XC26"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AX04",
"display": "Lenalidomide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Lenalidomide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Lenalidomid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AX",
"display": "Other immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AX04",
"display": "L04AX04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2005-10-11T00:00:00Z",
"display": "2005-10-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AX04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02BB04",
"display": "Enzalutamide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Enzalutamide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Enzalutamid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02BB",
"display": "Anti-androgens"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02BB04",
"display": "L02BB04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2014-01-02T00:00:00Z",
"display": "2014-01-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02BB04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XL04",
"display": "Tisagenlecleucel",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Tisagenlecleucel"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tisagenlekleucel"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XL",
"display": "Antineoplastic cell and gene therapy"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX71",
"display": "Tisagenlecleucel"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XL04",
"display": "L01XL04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-09-09T00:00:00Z",
"display": "2022-09-09T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XL04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01DB02",
"display": "Daunorubicin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Daunorubicin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Daunorubicin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01DB",
"display": "Anthracyclines and related substances"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01DB02",
"display": "L01DB02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01DB02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L02AB02",
"display": "Medroxyprogesterone",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Medroxyprogesterone"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Medroksyprogesteron"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02AB",
"display": "Progestogens"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02AB02",
"display": "L02AB02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02AB02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XM03",
"display": "Olutasidenib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Olutasidenib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Olutasidenib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XM",
"display": "Isocitrate dehydrogenase (IDH) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XM03",
"display": "L01XM03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2025-01-01T00:00:00Z",
"display": "2025-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XM03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX17",
"display": "Capmatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Capmatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Kapmatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX17",
"display": "L01EX17"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-11-11T00:00:00Z",
"display": "2020-11-11T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX17"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01DB01",
"display": "Doxorubicin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Doxorubicin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Doksorubicin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01DB",
"display": "Anthracyclines and related substances"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01DB01",
"display": "L01DB01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01DB01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AH01",
"display": "Sirolimus",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sirolimus"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sirolimus"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AH",
"display": "Mammalian target of rapamycin (mTOR) kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA10",
"display": "Sirolimus"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AH01",
"display": "L04AH01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2023-12-05T00:00:00Z",
"display": "2023-12-05T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AH01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AC23",
"display": "Olokizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Olokizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Olokizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AC",
"display": "Interleukin inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AC23",
"display": "L04AC23"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AC23"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA03",
"display": "Antilymphocyte immunoglobulin (horse)",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Antilymphocyte immunoglobulin (horse)"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Antilymfocyttimmunglobulin (hest)"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA03",
"display": "L04AA03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01FX22",
"display": "Loncastuximab tesirine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Loncastuximab tesirine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Lonkastuksimabtesirin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01FX",
"display": "Other monoclonal antibodies and antibody drug conjugates"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01FX22",
"display": "L01FX22"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2022-05-06T00:00:00Z",
"display": "2022-05-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01FX22"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AB15",
"display": "Ropeginterferon alfa-2b",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Ropeginterferon alfa-2b"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Ropeginterferon alfa-2b"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AB",
"display": "Interferons"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AB15",
"display": "L03AB15"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2017-12-01T00:00:00Z",
"display": "2017-12-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AB15"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EB07",
"display": "Dacomitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Dacomitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Dakomitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EB",
"display": "Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE47",
"display": "Dacomitinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EB07",
"display": "L01EB07"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EB07"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX12",
"display": "Larotrectinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Larotrectinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Larotrektinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE53",
"display": "Larotrectinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX12",
"display": "L01EX12"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-01-04T00:00:00Z",
"display": "2021-01-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX12"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX02",
"display": "Asparaginase",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Asparaginase"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Asparaginase"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX02",
"display": "L01XX02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XE33",
"display": "Palbociclib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Palbociclib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Palbosiklib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE33",
"display": "L01XE33"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2015-07-06T00:00:00Z",
"display": "2015-07-06T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE33"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L01XE47",
"display": "Dacomitinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Dacomitinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Dakomitinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE",
"display": "Protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XE47",
"display": "L01XE47"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2018-07-11T00:00:00Z",
"display": "2018-07-11T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2021-03-02T00:00:00Z",
"display": "2021-03-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XE47"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L02AA01",
"display": "Diethylstilbestrol",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Diethylstilbestrol"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Dietylstilbøstrol"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L02AA",
"display": "Estrogens"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L02AA01",
"display": "L02AA01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L02AA01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX09",
"display": "Miltefosine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Miltefosine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Miltefosin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX09",
"display": "L01XX09"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2020-01-06T00:00:00Z",
"display": "2020-01-06T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX09"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L03AB02",
"display": "Interferon beta natural",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Interferon beta natural"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Naturlig interferon beta"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AB",
"display": "Interferons"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AB02",
"display": "L03AB02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AB02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EX18",
"display": "Avapritinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Avapritinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Avapritinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EX",
"display": "Other protein kinase inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EX18",
"display": "L01EX18"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-10-04T00:00:00Z",
"display": "2020-10-04T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EX18"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AD05",
"display": "Fotemustine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Fotemustine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Fotemustin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AD",
"display": "Nitrosoureas"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AD05",
"display": "L01AD05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AD05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA28",
"display": "Belatacept",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Belatacept"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Belatacept"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA28",
"display": "L04AA28"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2010-03-16T00:00:00Z",
"display": "2010-03-16T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA28"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01BC52",
"display": "Fluorouracil, combinations",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Fluorouracil, combinations"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Fluorouracil, kombinasjoner"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01BC",
"display": "Pyrimidine analogues"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01BC52",
"display": "L01BC52"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01BC52"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AC01",
"display": "Thiotepa",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Thiotepa"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Tiotepa"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AC",
"display": "Ethylene imines"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AC01",
"display": "L01AC01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AC01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XK01",
"display": "Olaparib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Olaparib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Olaparib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XK",
"display": "Poly (ADP-ribose) polymerase (PARP) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX46",
"display": "Olaparib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XK01",
"display": "L01XK01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XK01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01ED04",
"display": "Brigatinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Brigatinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Brigatinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01ED",
"display": "Anaplastic lymphoma kinase (ALK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE43",
"display": "Brigatinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01ED04",
"display": "L01ED04"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01ED04"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AX13",
"display": "Glatiramer acetate",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Glatiramer acetate"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Glatirameracetat"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AX",
"display": "Other immunostimulants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AX13",
"display": "L03AX13"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2003-01-30T00:00:00Z",
"display": "2003-01-30T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AX13"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XH02",
"display": "Romidepsin",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Romidepsin"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Romidepsin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XH",
"display": "Histone deacetylase (HDAC) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX39",
"display": "Romidepsin"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XH02",
"display": "L01XH02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XH02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EK02",
"display": "Cediranib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Cediranib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Cediranib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EK",
"display": "Vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE32",
"display": "Cediranib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EK02",
"display": "L01EK02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EK02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AX06",
"display": "Pomalidomide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pomalidomide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pomalidomid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AX",
"display": "Other immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AX06",
"display": "L04AX06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2013-06-28T00:00:00Z",
"display": "2013-06-28T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AX06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L03AB05",
"display": "Interferon alfa-2b",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Interferon alfa-2b"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Interferon alfa-2b"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L03AB",
"display": "Interferons"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L03AB05",
"display": "L03AB05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L03AB05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XJ02",
"display": "Sonidegib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Sonidegib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Sonidegib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XJ",
"display": "Hedgehog pathway inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX48",
"display": "Sonidegib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XJ02",
"display": "L01XJ02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XJ02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01ED01",
"display": "Crizotinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Crizotinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Krizotinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01ED",
"display": "Anaplastic lymphoma kinase (ALK) inhibitors"
}
},
{
"code": "previousVersion",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XE16",
"display": "Crizotinib"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01ED01",
"display": "L01ED01"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2020-12-14T00:00:00Z",
"display": "2020-12-14T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01ED01"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX11",
"display": "Estramustine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Estramustine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Estramustin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX11",
"display": "L01XX11"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX11"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EE05",
"display": "Mirdametinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Mirdametinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Mirdametinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EE",
"display": "Mitogen-activated protein kinase (MEK) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EE05",
"display": "L01EE05"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2025-01-01T00:00:00Z",
"display": "2025-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EE05"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01EJ03",
"display": "Pacritinib",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Pacritinib"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Pakritinib"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01EJ",
"display": "Janus-associated kinase (JAK) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01EJ03",
"display": "L01EJ03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2021-11-08T00:00:00Z",
"display": "2021-11-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01EJ03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01AD03",
"display": "Semustine",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Semustine"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Semustin"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01AD",
"display": "Nitrosoureas"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01AD03",
"display": "L01AD03"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01AD03"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AX02",
"display": "Thalidomide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Thalidomide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Talidomid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AX",
"display": "Other immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AX02",
"display": "L04AX02"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AX02"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA19",
"display": "Gusperimus",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Gusperimus"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Gusperimus"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA19",
"display": "L04AA19"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2003-04-25T00:00:00Z",
"display": "2003-04-25T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA19"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L04AA08",
"display": "Daclizumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Daclizumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Daklizumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AA",
"display": "Selective immunosuppressants"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AA08",
"display": "L04AA08"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2002-02-08T00:00:00Z",
"display": "2002-02-08T00:00:00Z"
}
},
{
"code": "toDate",
"valueCoding": {
"code": "2008-01-01T00:00:00Z",
"display": "2008-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AA08"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Slettet",
"display": "Slettet"
}
}
]
},
{
"code": "L04AB06",
"display": "Golimumab",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Golimumab"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Golimumab"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L04AB",
"display": "Tumor necrosis factor alpha (TNF-alpha) inhibitors"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L04AB06",
"display": "L04AB06"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2010-01-01T00:00:00Z",
"display": "2010-01-01T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L04AB06"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
},
{
"code": "L01XX35",
"display": "Anagrelide",
"designation": [
{
"language": "en",
"use": {
"code": "term-name"
},
"value": "Anagrelide"
},
{
"language": "no",
"use": {
"code": "term-name"
},
"value": "Anagrelid"
}
],
"property": [
{
"code": "parentATC",
"valueCoding": {
"system": "https://api.legemiddelverket.no/FHIR-R4/CodeSystem/849bc27b-a66d-49ad-9389-d8f19d63b480",
"code": "L01XX",
"display": "Other antineoplastic agents"
}
},
{
"code": "ATCCode",
"valueCoding": {
"code": "L01XX35",
"display": "L01XX35"
}
},
{
"code": "fromDate",
"valueCoding": {
"code": "2006-01-02T00:00:00Z",
"display": "2006-01-02T00:00:00Z"
}
},
{
"code": "internalCode",
"valueCoding": {
"code": "L01XX35"
}
},
{
"code": "internalTermStatus",
"valueCoding": {
"code": "Godkjent WHO",
"display": "Godkjent WHO"
}
}
]
}
]
}